```
=> b reg
FILE 'REGISTRY' ENTERED AT 10:08:59 ON 04 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 MAY 2004  HIGHEST RN 678693-82-8
DICTIONARY FILE UPDATES:   2 MAY 2004  HIGHEST RN 678693-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que l9
L9            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  142880-36-2/RN


=> d ide l9

L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   142880-36-2  REGISTRY
CN   Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-
     2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-
     oxoethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]-
OTHER NAMES:
CN   CS 610
CN   Galardin
CN   GM 6001
CN   Ilomastat
FS   STEREOSEARCH
MF   C20 H28 N4 O4
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CA, CANCERLIT,
       CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSDRUGNEWS,
       IMSPATENTS, IMSRESEARCH, MEDLINE, PHAR, PROMT, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL
     Other Sources:   WHO

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

80 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
82 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d que l10
L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON 421553-77-7/RN

=> d ide l10

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN **421553-77-7** REGISTRY
CN Butanediamide, N1-[(1S)-2-[(2-aminoethyl)amino]-1-methyl-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN IC 3
FS STEREOSEARCH
MF C13 H26 N4 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Searched by P. Ruppel

```
=> b home
FILE 'HOME' ENTERED AT 10:09:38 ON 04 MAY 2004

=>
```

```
=> b reg
FILE 'REGISTRY' ENTERED AT 09:55:27 ON 04 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 MAY 2004  HIGHEST RN 678693-82-8
DICTIONARY FILE UPDATES:   2 MAY 2004  HIGHEST RN 678693-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d que l17
L13             STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  28

STEREO ATTRIBUTES: NONE
L17         120 SEA FILE=REGISTRY SSS FUL L13


=> d que l18
L15             STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L18 178 SEA FILE=REGISTRY SSS FUL L15

=>

```
=> b hcaplus
FILE 'HCAPLUS' ENTERED AT 10:02:20 ON 04 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 May 2004  VOL 140 ISS 19
FILE LAST UPDATED: 3 May 2004  (20040503/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d que l20 nos
L13             STR
L15             STR
L17         120 SEA FILE=REGISTRY SSS FUL L13
L18         178 SEA FILE=REGISTRY SSS FUL L15
L19         142 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L17 OR L18
L20          63 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L19 AND P/DT


=> d ibib abs hitstr l20 1-63

L20  ANSWER 1 OF 63  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:        2004:310824  HCAPLUS
TITLE:                   Compounds and methods for the modulation of CD154 for
                         preventing thrombosis and coagulation and reducing
                         activation of cells in inflammatory response
INVENTOR(S):             Phillips, David; Yan, Yibing; Alaimo, Lisa; Prasad,
                         Srinivasa
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S.
                         Pat. Appl. 2004 48,803.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  3
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     US 2004072750      A1   20040415      US 2003-376425   20030228
     US 2002165166      A1   20021107      US 2001-2585     20011130
     WO 2002089730      A2   20021114      WO 2002-US13900  20020503
     WO 2002089730      A3   20030213
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
```

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004048803 A1 20040311 US 2003-368947 20030217
PRIORITY APPLN. INFO.: US 2001-289049P P 20010503
US 2001-2585 A1 20011130
WO 2002-US13900 A2 20020503
US 2003-368947 A2 20030217

AB The invention relates to compds. that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic and/or coagulation process and/or reducing the activation of cells involved in an inflammatory response. The invention also relates to methods useful for identifying such compds. The invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compns. and methods to treat injury and disease related to such biol. processes. GPIIb/IIIa inhibition with eptifibatide lowered levels of sCD40L and RANTES post stenting, conferring antiinflammatory as well as antithrombotic effects.

IT INDEXING IN PROGRESS

IT **142880-36-2**, GM6001
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloproteinase inhibitor, soluble CD154 release inhibition by; CD154 modulator for prevention of thrombosis, coagulation, and inflammatory response)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:252305 HCAPLUS
DOCUMENT NUMBER: 140:281409
TITLE: Inhibition or activation of ADAM9 and ADAM15 for treatment of vascularization-related disease and wound healing
INVENTOR(S): Blobel, Carl P.; Horiuchi, Keisuke; Weskamp, Gisela; Preissner, Klaus
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA;

University of Mannheim/heidelberg;
Justus-Liebig-Universitaet Giessen; Hammes, Hans-Peter
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024089	A2	20040325	WO 2003-US28751	20030911

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-409858P P 20020911

AB Inhibition of neovascularization is achieved by exposing a tissue susceptible to neovascularization to a therapeutic agent effective to inhibit ADAM9 and/or ADAM15. The therapeutic agent may be, for example, an antibody, a small mol. therapeutic, an antisense or RNAi therapeutic, or an agent for introducing targeted mutations in the genetic sequence for ADAM9 and/or ADAM15. Thus, an individual suffering from a condition associated with pathol. neovascularization is treated by administration of a therapeutic agent effective to inhibit an ADAM9 or ADAM15. Activation of ADAM9 or ADAM15 can be used for promotion of neovascularization, for example to facilitate wound healing, perfusion or circulation. In this case, the therapeutic agent used is one which enhances the active amount of ADAM9 and/or ADAM15. Inhibition or activation of ADAM9 and/or ADAM15 in accordance with the methods of the invention provides an attractive alternative to targeting of other ADAM species, such as ADAM10, because neither ADAM9 nor ADAM15 appears to be essential for development or maintenance. Thus, side effects are minimized. The growth of B16F10 melanoma tumors was reduced in ADAM9-/- and ADAM15-/- mice compared to wild-type mice.

IT **143457-40-3**, TAPI
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ADAM9 or ADAM15 inhibitor; ADAM9 and ADAM15 inhibition or activation for treatment of vascularization-related disease and wound healing)

RN 143457-40-3 HCAPLUS

CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 3 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:203542 HCAPLUS
DOCUMENT NUMBER: 140:247105
TITLE: Metalloproteinase inhibitor compounds and methods for the modulation of CD154, and use for stabilizing the thrombotic and/or coagulation process and/or reducing the activation of cells involved in an inflammatory response
INVENTOR(S): Phillips, David; Andre, Patrick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of Appl. No. PCT/US2002/13900.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004048803	A1	20040311	US 2003-368947	20030217
US 2002165166	A1	20021107	US 2001-2585	20011130
WO 2002089730	A2	20021114	WO 2002-US13900	20020503
WO 2002089730	A3	20030213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004072750	A1	20040415	US 2003-376425	20030228

PRIORITY APPLN. INFO.:

US 2001-289049P	P	20010503
US 2001-2585	A1	20011130
WO 2002-US13900	A2	20020503
US 2003-368947	A2	20030217

AB The invention relates to compds. that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic and/or coagulation process and/or reducing the activation of cells involved in an inflammatory response. Compds. of the invention include metalloproteinase inhibitors. The invention also relates to methods useful for identifying such compds. The invention also relates to the treatment of platelets for

transfusion with metalloproteinase inhibitors to treat or prevent inflammation.. The invention also includes compns. and methods to treat injury and disease related to such biol. processes.

IT **142880-36-2**, Galardin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloproteinase inhibitor compds. and methods for modulation of CD154, and use for stabilizing thrombotic and/or coagulation process and/or reducing activation of cells involved in inflammatory response)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 4 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:875135 HCAPLUS
DOCUMENT NUMBER: 139:333136
TITLE: Combination therapy using a proteasome/ubiquitination inhibitor and a matrix metalloproteinase inhibitor to treat a catabolic state and/or cachexia in a patient
INVENTOR(S): Strous, Gerardus Jacobus Antonius Maria; Van Kerkhof, Petrus Johannes Maria
PATENT ASSIGNEE(S): Universiteit Utrecht Holding B.V., Neth.; UMC Utrecht Holding B.V.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090777	A1	20031106	WO 2003-NL303	20030424

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1356819 A1 20031029 EP 2002-76675 20020425
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: EP 2002-76675 A 20020425
US 2002-375557P P 20020425

AB The invention relates to the field of proteins, more specifically to proteins that are located on the surface of cells. The invention provides a method for upregulating the bioavailability of a cell surface receptor comprising decreasing both the uptake and/or degradation of said receptor and the extracellular cleaving of the receptor. The invention further provides pharmaceutical compns. for upregulating the bioavailability of a growth hormone receptor, comprising a proteasome/ubiquitination inhibitor and a matrix metalloproteinase inhibitor, as well as the use of these pharmaceutical compns. for the manufacture of a medicament for increasing anabolic conditions in human patients suffering from a catabolic state and/or cachexia.

IT **142880-36-2**, GM6001
RL: PAC (Pharmacological activity); BIOL (Biological study)
(proteasome/ubiquitination inhibitor-matrix metalloproteinase inhibitor combination to treat catabolic state and/or cachexia)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:591202 HCAPLUS
DOCUMENT NUMBER: 139:145836
TITLE: Synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications
INVENTOR(S): Fourie, Anne; Karlsson, Lars; Coles, Fawn
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062263	A2	20030731	WO 2003-US1327	20030115
WO 2003062263	A3	20040115		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003166037 A1 20030904 US 2002-50200 20020116

PRIORITY APPLN. INFO.: US 2002-50200 A 20020116

AB The present invention describes synthetic peptide substrates of the metalloproteases, agggrecanase-1 and/or -2 suitable for assays of enzyme activity. The substrates are peptides less than 40 amino acids in length having a cleavage site between Glu on the N-terminal side of the cleavage site and a non-polar or uncharged residue on the C-terminal side of the cleavage site. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases.

IT **163958-74-5**

RL: BSU (Biological study, unclassified); BIOL (Biological study) (aggrecanase inhibition by; synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications)

RN 163958-74-5 HCAPLUS

CN L-Alaninamide, N-[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 6 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:334655 HCAPLUS

DOCUMENT NUMBER: 138:333105

TITLE: Composition and method for minimizing or avoiding adverse effects of vesicants

INVENTOR(S): Lerner, David S.; Schultz, Gregory

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2003083321 A1 20030501 US 2002-256215 20020925
WO 2003094954 A1 20031120 WO 2002-US30597 20020925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-325015P P 20010925

AB The invention pertains to compns. and methods to treat the adverse effects of mustard chems. and other toxic compds., such as chemical warfare agents, exposure to which normally induces vesicating type response in mammals. In a rodent eye model at fixed concns. of such a vesicant, compns. comprising (a) a matrix metalloproteinase inhibitor, MMPI, and (b) a protease inhibitor, PI, such as a serine protease inhibitor, SPI, a significant reduction in morbidity is achieved with increased concns. of the compns. of this invention, as compared with an MMPI inhibitor alone or vehicle alone. Furthermore, compns. comprising the MMPI, the SPI, and in addition, an anti-inflammatory compound, in a vehicle appropriate to the type of tissue damage to be protected against from vesicant exposure, achieves both reduction in total tissue damage and inflammation, as compared with anti-inflammatory composition alone. Chems. having more than one property, such as MMPI and anti-inflammatory agent properties, are also disclosed. Certain combinations disclosed are applied to treat injuries due to acids and bases.

IT **142880-36-2**, Ilomastat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(composition and method for minimizing or avoiding adverse effects of vesicants)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 7 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:261714 HCAPLUS
DOCUMENT NUMBER: 138:292821
TITLE: Method of preparing basement membrane, method of constructing basement membrane specimen, reconstituted artificial tissue using the basement membrane specimen and process for producing the same

INVENTOR(S): Mochitate, Katsumi
PATENT ASSIGNEE(S): Japan Science and Technology Corporation, Japan
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026712	A1	20030403	WO 2002-JP9841	20020925
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
JP 2003093050	A2	20030402	JP 2001-292510	20010925
JP 2003093053	A2	20030402	JP 2001-292676	20010925
JP 2003169846	A2	20030617	JP 2002-278243	20020924
JP 2003169847	A2	20030617	JP 2002-278244	20020924

PRIORITY APPLN. INFO.:
JP 2001-292510 A 20010925
JP 2001-292675 A 20010925
JP 2001-292676 A 20010925
JP 2001-292677 A 20010925
JP 2002-278243 A 20020924
JP 2002-278244 A 20020924

AB A basement membrane is formed by culturing cells on a substrate wherein the basal face of cells capable of forming a basement membrane has been coated with a polymer having a sugar chain capable of localizing a receptor having an effect of accumulating basement membrane-constituting components. The basement membrane specimen is constructed by treating cells, which are capable of forming a basement membrane and have been adhered to a support via the basement membrane, with a surfactant to solubilize lipid components of the cells and solubilizing proteins remaining on the basement membrane surface with the use of a mixture of an alkali solution with a protease inhibitor. An artificial tissue is obtained by inoculating and culturing desired cells capable of forming a basement membrane. Using a hydrophobic bond adsorption polymer having a linear carbon skeleton with a hydrophobic nature and a functional group capable of reacting with a protein (for example, an alternate copolymer of Me vinyl ether with maleic anhydride), a protein support is tentatively adhered to a plastic surface and a basement membrane specimen or an artificial tissue is formed thereon. Thus, the protein support carrying the basement membrane specimen or the artificial tissue thereon can be phys. separated from the plastic surface when needed. Sugar chain-containing vinyl polymer (PV-GluNAc, PV-CA, or PV-Lam) was applied to fibrous collagen gel formed on a polyethylene terephthalate membrane in a culture well for culture of human pulmonary artery vascular endothelial cells to obtain a basement membrane.

IT **142880-36-2**, GM6001
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(culture with; method of preparing basement membrane with sugar chain-containing polymer-coated substrate for reconstituted artificial tissue)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:154681 HCAPLUS
DOCUMENT NUMBER: 138:180673
TITLE: Systems and methods for screening pharmaceutical chemicals
INVENTOR(S): Elson, Elliot; McConnaughey, William B.; Wakatsuki, Tetsuro
PATENT ASSIGNEE(S): Washington University in St. Louis, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016860	A2	20030227	WO 2002-US25761	20020814
WO 2003016860	A3	20030612		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003064358	A1	20030403	US 2002-219097	20020814

PRIORITY APPLN. INFO.: US 2001-312322P P 20010814

AB A method for obtaining a response of a tissue model system to an activator includes contacting a bio-artificial tissue model system with an activator and measuring cellular mech. response thereto of at least one of contractile force and tissue stiffness. A method for obtaining a response of a tissue model system to an activator includes contacting a bio-artificial tissue model system with an activator and measuring cellular mech. response thereto of at least one of contractile force and hysteresis.

IT **142880-36-2**, GM6001
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(systems and methods for screening pharmaceutical chems.)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 9 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:57854 HCAPLUS
DOCUMENT NUMBER: 138:100922
TITLE: A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
INVENTOR(S): Tortorella, Michael; Wang, Jinhai; Balhorn, Rodney L.
PATENT ASSIGNEE(S): Enzyme Systems Products, Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005956	A2	20030123	WO 2002-US21780	20020709
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003114529	A1	20030619	US 2002-192283	20020709

PRIORITY APPLN. INFO.: US 2001-303989P P 20010709

AB The present invention concerns the generation of hydroxamic acid thrombospondin-peptide analogs that inhibit aggrecanase activity. These analogs are useful in the treatment of diseases characterized by cartilage degradation, such as osteoarthritis, rheumatoid arthritis spondylarthropathies, and septic arthritis. The invention describes a novel small mol., enzyme inhibitor that binds both the enzyme and its naturally occurring substrate.

IT **485799-20-0DP**, peptide conjugates **485799-20-0P 485799-21-1P 485799-22-2P 485799-23-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(aggrecanase-inhibiting hydroxamic acid thrombospondin peptide analog for treatment of osteoarthritis and spondylarthropathies)

RN 485799-20-0 HCAPLUS

CN L-Threonine, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-L-glutaminyl-L-alanylglycylglycyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-α-aspartyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 485799-20-0 HCAPLUS
CN L-Threonine, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-L-glutaminyl-L-alanylglycylglycyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-α-aspartyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 485799-21-1 HCAPLUS
CN L-Threonine, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-glutaminyl-L-alanylglycylglycyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-α-aspartyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Searched by P. Ruppel

PAGE 2-A



PAGE 2-B



RN 485799-22-2 HCAPLUS
CN L-Threonine, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-glutaminyl-L-alanylglycylglycyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-α-aspartyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Searched by P. Ruppel

PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 485799-23-3 HCAPLUS
CN L-Threonine, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-L-methionyl-L-α-aspartyl-L-glutaminyl-L-leucyl-L-glutaminyl-L-α-aspartyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-glutaminyl-L-alanylglycylglycyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-prolyl-L-tryptophylglycyl-L-α-aspartyl-L-seryl-L-seryl-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B

PAGE 2-A



PAGE 2-B



PAGE 2-C



L20 ANSWER 10 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:850312 HCAPLUS
DOCUMENT NUMBER: 137:346178
TITLE: Compounds and methods for the modulation of CD154 for

treating thrombosis and inflammation

INVENTOR(S): Yan, Yibing; Phillips, David; Alaimo, Lisa; Andre, Patrick; Alves, Veronica

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp.
CODEN: USXXCO

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002165166	A1	20021107	US 2001-2585	20011130
WO 2002089730	A2	20021114	WO 2002-US13900	20020503
WO 2002089730	A3	20030213		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1399466	A2	20040324	EP 2002-734145	20020503

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004048803	A1	20040311	US 2003-368947	20030217
US 2004072750	A1	20040415	US 2003-376425	20030228

PRIORITY APPLN. INFO.:

US 2001-289049P	P	20010503
US 2001-2585	A	20011130
WO 2002-US13900	W	20020503
US 2003-368947	A2	20030217

AB The present invention relates to compds. that are capable of modulating CD154 mobilization and that are useful for stabilizing the thrombotic process and reducing the activation of cells involved in an inflammatory response. The present invention also relates to methods useful for identifying such compds. The present invention also relates to the treatment of platelets for transfusion with metalloproteinase inhibitors to treat or prevent inflammation. The present invention also includes compns. and methods to treat injury and disease related to such biol. processes. Metalloproteinase inhibitors TAPI-1 and TIMP-2 inhibited platelet aggregation and soluble CD154 release.

IT **142880-36-2**, Galardin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modulation of CD154 for treating thrombosis and inflammation)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 11 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:675786 HCAPLUS
DOCUMENT NUMBER: 137:210945
TITLE: Composition and method using matrix metalloproteinase inhibitors for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease
INVENTOR(S): Deleve, Laurie
PATENT ASSIGNEE(S): University of Southern California, USA
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002067870	A2	20020906	WO 2002-US8041	20020227
WO 2002067870	A3	20021121		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002147158	A1	20021010	US 2002-86072	20020227
EP 1379130	A2	20040114	EP 2002-719257	20020227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-271780P P 20010227
WO 2002-US8041 W 20020227

AB Matrix metalloproteinase ("MMP") inhibitors are used to prevent and treat Sinusoidal Obstruction Syndrome ("SOS"). In particular, the present invention provides a method of preventing and treating chemotherapy- and radiation-induced liver disease. This invention can be given prophylactically to patients who are receiving high dose chemotherapy and/or radiation and who are at risk for SOS or radiation-induced liver disease. This method may also be used to treat patients therapeutically who have developed SOS or radiation-induced liver disease. Because the development of chemotherapy or radiation-induced liver disease limits patient eligibility for several chemotherapeutic drugs, the present

invention increases patient eligibility for many of these drugs. Rats with monocrotaline-induce hepatic venoocclusive disease were treated with doxycycline.

IT **142880-36-2**, Ilomastat
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix metalloproteinase inhibitors for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 12 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:556104 HCAPLUS
DOCUMENT NUMBER: 137:109489
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randal J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 34 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002099013	A1	20020725	US 2001-933708	20010822

PRIORITY APPLN. INFO.:

US 2000-247556P	P	20001114
US 2000-247558P	P	20001114
US 2000-247559P	P	20001114
US 2000-247560P	P	20001114
US 2000-247561P	P	20001114
US 2000-247594P	P	20001114
US 2000-247595P	P	20001114
US 2000-247606P	P	20001114
US 2000-247607P	P	20001114
US 2000-247608P	P	20001114
US 2000-247609P	P	20001114
US 2000-247610P	P	20001114
US 2000-247611P	P	20001114
US 2000-247612P	P	20001114

US 2000-247620P	P	20001114
US 2000-247621P	P	20001114
US 2000-247634P	P	20001114
US 2000-247635P	P	20001114
US 2000-247698P	P	20001114
US 2000-247699P	P	20001114
US 2000-247700P	P	20001114
US 2000-247701P	P	20001114
US 2000-247702P	P	20001114
US 2000-247797P	P	20001114
US 2000-247798P	P	20001114
US 2000-247799P	P	20001114
US 2000-247800P	P	20001114
US 2000-247801P	P	20001114
US 2000-247802P	P	20001114
US 2000-247803P	P	20001114
US 2000-247804P	P	20001114
US 2000-247805P	P	20001114
US 2000-247807P	P	20001114
US 2000-247832P	P	20001114
US 2000-247833P	P	20001114
US 2000-247926P	P	20001114
US 2000-247927P	P	20001114
US 2000-247928P	P	20001114
US 2000-247929P	P	20001114
US 2000-247930P	P	20001114

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

IT **142880-36-2**, Ilomastat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 13 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:521462 HCAPLUS
DOCUMENT NUMBER: 137:88442
TITLE: Incensole and furanogermacrens and compounds in

treatment for inhibiting neoplastic lesions and microorganisms
INVENTOR(S): Shanahan-Pendergast, Elisabeth
PATENT ASSIGNEE(S): Ire.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053138	A2	20020711	WO 2002-IE1	20020102
WO 2002053138	A3	20020919		
W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI, ML, MR, NE, SN, TD, TG				
EP 1351678	A2	20031015	EP 2002-727007	20020102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: IE 2001-2 A 20010102
WO 2002-IE1 W 20020102

OTHER SOURCE(S): MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrens, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immundysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacren and their mixture showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

IT **142880-36-2**, Ilomastat
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 14 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353989 HCAPLUS

DOCUMENT NUMBER: 136:345514
TITLE: Cosmetic compositions containing a matrix metalloproteinase inhibitor and estrogen
INVENTOR(S): Lerner, David S.; Schultz, Gregory
PATENT ASSIGNEE(S): Quick Med Technologies Inc., USA; University of Florida Research Foundation, Inc.
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002054922	A1	20020509	US 2001-896566	20010629
US 6713074	B2	20040330		

PRIORITY APPLN. INFO.: US 2000-215087P P 20000629

AB A cosmetic topical formulation containing a matrix metalloproteinase (MMP) inhibitor, e.g., Ilomastat, is described for diminishing skin wrinkling, fine line, and improving skin tone. The topical formulation also contains a natural estrogen, e.g., a true estrogen compound, such as 17β-estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal prepns.), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMP inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethinyl estradiol and clomiphene citrate. The cosmetic topical formulation is safe and effective in diminishing wrinkling, and improving skin tone. Certain compns. of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. For example, a composition comprising black cohosh extract at 15 mL of extract per 100 g of gel and 10 mg of Ilomastat and 100 mL of generic cream carrier comprising 35% propylene glycol and the balance water and an acrylate gellant was formed by thorough mixing. The cream was applied to the forearms and then face and neck of a volunteer.

IT **142880-36-2**, Ilomastat
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compns. containing matrix metalloproteinase inhibitor and estrogen for prevention and reduction of skin wrinkles)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 15 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:332055 HCAPLUS
DOCUMENT NUMBER: 136:350543
TITLE: Metalloprotease inhibitors for treatment of angiogenesis
INVENTOR(S): Pan, Duojia; Rubin, Gerald M.; Zhang, Hongbing
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034289	A1	20020502	WO 2001-US45612	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6436629	B1	20020820	US 2000-697854	20001027
AU 2002020098	A5	20020506	AU 2002-20098	20011025
EP 1333856	A1	20030813	EP 2001-988593	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002132778	A1	20020919	US 2002-68591	20020206

PRIORITY APPLN. INFO.: US 2000-697854 A 20001027
WO 2001-US45612 W 20011025

AB The invention provides methods and compns. relating to Kuz involvement in angiogenesis. In various embodiments, the invention provides methods for modulating angiogenesis by specifically modulating the activity of Kuz in a vertebrate animal predetd. to have a pathogenic angiogenesis; and subsequently detecting a resultant angiogenic modulation in the animal. Methods are provided for identifying a modulator of angiogenesis by (a) contacting an angiogenic assay system comprising a predetd. amount of Kuz with a candidate agent, under conditions whereby but for the presence of the agent, the system provides a reference angiogenesis; and (b) detecting an agent-biased angiogenesis of the system.

IT **142880-36-2**, GM6001 **421553-77-7**, IC 3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metalloprotease inhibitors for treatment of angiogenesis)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 421553-77-7 HCAPLUS
CN Butanediamide, N1-[(1S)-2-[(2-aminoethyl)amino]-1-methyl-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 16 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:332011 HCAPLUS
DOCUMENT NUMBER: 136:355482
TITLE: Compositions comprising a polypeptide and an active agent
INVENTOR(S): Piccariello, Thomas; Olon, Lawrence P.; Kirk, Randall J.
PATENT ASSIGNEE(S): New River Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002034237	A1	20020502	WO 2001-US26142	20010822

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6716452	B1	20040406	US 2000-642820	20000822
AU 2001086599	A5	20020506	AU 2001-86599	20010822
EP 1311242	A1	20030521	EP 2001-966056	20010822

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-642820 A 20000822
WO 2001-US26142 W 20010822

AB Claimed are compns. comprising a polypeptide and an active agent covalently attached to the polypeptide and a method for delivery of an active agent to a patient by administering the composition to the patient. The peptide is a homopolymer of a naturally occurring amino acid or a heteropolymer of two or more naturally occurring amino acids. In an example, (Glu)n-cephalexin was prepared from Glu(OBut)NCA and cephalexin hydrochloride.

IT **142880-36-2**, Ilomastat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising a polypeptide and an active agent)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 17 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:184870 HCAPLUS
DOCUMENT NUMBER: 136:221543
TITLE: Cosmetic compositions containing matrix metalloproteinase inhibitor and estrogens
INVENTOR(S): Lerner, David S.; Schultz, Gregory
PATENT ASSIGNEE(S): Quick Med Technologies, Inc., USA; University of Florida Research Foundation, Inc.
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019982	A2	20020314	WO 2001-US20945	20010629
WO 2002019982	A3	20030724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,

HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001073115	A5	20020322	AU 2001-73115	20010629
EP 1359897	A2	20031112	EP 2001-952355	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004508317	T2	20040318	JP 2002-524467	20010629

PRIORITY APPLN. INFO.: US 2000-215087P P 20000629
WO 2001-US20945 W 20010629

AB The cosmetic topical formulation of this invention is directed toward diminishing skin wrinkling, fine lines, improving skin tone, and combinations. Preferably, the topical formulation contains a matrix metalloproteinase inhibitor, MMPI, and advantageously includes a natural estrogen, e.g., a true estrogen compound, such as 17β-estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal prepns.), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMPI inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethynylestradiol and clomiphene citrate. The cosmetic topical formulation is safe and effective diminishing wrinkling, and improving skin tone. Certain compns. of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking. Thus, a composition contained black cohosh extract (15 mL/100 g gel), 10 mg ilomastat and 100 mL generic cream carrier containing 35% propylene glycol, acrylic gel and the balance water.

IT **142880-36-2**, Ilomastat
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compns. containing matrix metalloproteinase inhibitor and estrogens)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 18 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:72042 HCAPLUS
DOCUMENT NUMBER: 136:135027
TITLE: Preparation of lysine-based peptide dendrimers as

matrix metalloprotease inhibitors

INVENTOR(S): Okamachi, Akira; Tamura, Tatsuya; Hayashi, Yoshiki; Nakamura, Teruo

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006227	A1	20020124	WO 2001-JP6172	20010717

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2000-216790 A 20000718
JP 2000-398635 A 20001227

OTHER SOURCE(S): MARPAT 136:135027

GI



I

AB Title compds. [HONHCOCHR1CHR2CONHCHR3CONR4CH2(CH2CH2O)3CH2CH2CH2NHCOR; R1 = H, O, C1-8 alkyl, C1-8 alkoxy, C2-8 alkenyl; R2, R3 independently = cycloalkyl, C1-8 alkyl; R4 = H, C1-4 alkyl; R = alkyleneamino] and salts are prepared and formulation discussed as matrix metalloprotease (MMP) inhibitors useful in improving the retention at an affected part of a living body, such as shoulder periarthritis. Thus, the title compound I was prepared from H2NCH2[(CH2)2O]3CH2CH2CH2NH2, N-9-Fluorenylmethoxycarbonyltryptophan, and N-α,ω1,ω2-Tris(benzyloxycarbonyl)-D-arginine and biol. tested for matrix metalloprotease inhibition effect.

IT **387825-45-8P 391902-89-9P 391902-96-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lysine-based peptide dendrimers as matrix metalloprotease inhibitors)

RN 387825-45-8 HCAPLUS
CN D-Argininamide, D-arginyl-N-[(16S)-19-[2-(hydroxyamino)-2-oxoethyl]-16-(1H-indol-3-ylmethyl)-21-methyl-15,18-dioxo-4,7,10-trioxa-14,17-diazadocos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-89-9 HCAPLUS
CN Butanediamide, N1-[(1S,19R)-19,24-diamino-24-imino-1-(1H-indol-3-ylmethyl)-2,18-dioxo-7,10,13-trioxa-3,17,23-triazatetracos-1-yl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Searched by P. Ruppel

PAGE 1-B



RN 391902-96-8 HCAPLUS
CN D-Argininamide, D-arginyl-D-arginyl-N-[(16S)-19-[2-(hydroxyamino)-2-oxoethyl]-16-(1H-indol-3-ylmethyl)-21-methyl-15,18-dioxo-4,7,10-trioxa-14,17-diazadocos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **391902-86-6P 391902-87-7P 391902-88-8P**
391902-90-2P 391902-91-3P 391902-92-4P
391902-93-5P 391902-94-6P 391902-95-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of lysine-based peptide dendrimers as matrix metalloprotease inhibitors)

RN 391902-86-6 HCAPLUS
CN 2,15,18,21-Tetraoxa-3,8,11,25-tetraazahexacosan-26-oic acid, 9-(1H-indol-3-ylmethyl)-6-(2-methylpropyl)-4,7,10-trioxo-1-phenyl-, 1,1-dimethylethyl ester, (9S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-87-7 HCAPLUS
CN Butanediamide, N1-[(1S)-16-amino-1-(1H-indol-3-ylmethyl)-2-oxo-7,10,13-trioxa-3-azahexadec-1-yl]-2-(2-methylpropyl)-N4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Searched by P. Ruppel

PAGE 1-B

RN 391902-88-8 HCAPLUS
CN 2,15,18,21-Tetraoxa-3,8,11,25,31,33-hexaazatetratriacont-31-en-34-oic acid, 9-(1H-indol-3-ylmethyl)-6-(2-methylpropyl)-4,7,10,26-tetraoxo-1-phenyl-27,32-bis[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester, (9S,27R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-90-2 HCAPLUS
CN 2,15,18,21-Tetraoxa-3,8,11,25,31,33-hexaazatetratriacont-31-en-34-oic acid, 27-[[(1,1-dimethylethoxy)carbonyl]amino]-9-(1H-indol-3-ylmethyl)-6-(2-methylpropyl)-4,7,10,26-tetraoxo-1-phenyl-32-[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester, (9S,27R)- (9CI) (CA INDEX NAME)

Searched by P. Ruppel

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-91-3 HCAPLUS
CN 2,15,18,21-Tetraoxa-3,8,11,25,31,33-hexaazatetratriacont-31-en-34-oic acid, 27-amino-9-(1H-indol-3-ylmethyl)-6-(2-methylpropyl)-4,7,10,26-tetraoxo-1-phenyl-32-[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester, (9S,27R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-92-4 HCAPLUS
CN D-Ornithinamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[(phenylmethoxy)carbonyl]-D-ornithyl-N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N-[(16S)-16-(1H-indol-3-ylmethyl)-19-(2-methylpropyl)-15,18,21-trioxo-24-phenyl-4,7,10,23-tetraoxa-14,17,22-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-93-5 HCAPLUS
CN D-Ornithinamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[(1,1-dimethylethoxy)carbonyl]-D-ornithyl-N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N-[(16S)-16-(1H-indol-3-ylmethyl)-19-(2-methylpropyl)-15,18,21-trioxo-24-phenyl-4,7,10,23-tetraoxa-14,17,22-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-94-6 HCAPLUS
CN D-Ornithinamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-D-ornithyl-N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N-[(16S)-16-(1H-indol-3-ylmethyl)-19-(2-methylpropyl)-15,18,21-trioxo-24-phenyl-4,7,10,23-tetraoxa-14,17,22-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 391902-95-7 HCAPLUS
CN D-Ornithinamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[(phenylmethoxy)carbonyl]-D-ornithyl-N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-D-ornithyl-N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N-[(16S)-16-(1H-indol-3-ylmethyl)-19-(2-methylpropyl)-15,18,21-trioxo-24-phenyl-4,7,10,23-tetraoxa-14,17,22-triazatetracos-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 109 THERE ARE 109 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 19 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:816500 HCAPLUS
DOCUMENT NUMBER: 135:362539
TITLE: Functional MRI agents for cancer imaging
INVENTOR(S): Meade, Thomas J.
PATENT ASSIGNEE(S): Research Corporation Technologies, USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082976	A2	20011108	WO 2001-US14470	20010504
WO 2001082976	A3	20020510		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
US 6673333	B1	20040106	US 2000-715859	20001117
EP 1278552	A2	20030129	EP 2001-931061	20010504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531872	T2	20031028	JP 2001-579849	20010504

PRIORITY APPLN. INFO.: US 2000-201816P P 20000504
US 2000-715859 A1 20001117
WO 2001-US14470 W 20010504

OTHER SOURCE(S): MARPAT 135:362539

Searched by P. Ruppel

AB The invention relates to novel magnetic resonance imaging contrast agents for imaging cancer. The agents comprise a Gd(III) ion bound to a first chelator such that the Gd(III) ion has coordination atoms in at least 7 coordination sites and a first tumor-associated activatable guarding moiety (TAAGM) covalently attached to the first chelator which hinders the rapid exchange of water in the remaining coordination sites of the Gd(III) ion. The TAAGM is capable of interacting with a cancer target substance such that the exchange of water in the remaining coordination sites of the first Gd(III) ion is increased. The TAAGM comprises groups which bind to β-glucuronidase.

IT **142880-36-2D**, GM 6001, conjugates with gadolinium complexes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(functional MRI agents containing enzyme-cleavable groups for use in cancer imaging)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 20 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:545522 HCAPLUS
DOCUMENT NUMBER: 135:127214
TITLE: Inhibitors for plasmodial invasion into erythrocytes
INVENTOR(S): Kawai, Satoru; Matsumoto, Jun; Matsuda, Hajime; Terao, Keiji; Haruki, Kosuke; Yoshino, Kohichiro
PATENT ASSIGNEE(S): Nippon Organon K. K., Japan
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052891	A1	20010726	WO 2001-JP336	20010119
W: JP				

PRIORITY APPLN. INFO.: JP 2000-48304 A 20000120

AB Inhibitors against the invasion of plasmodium into erythrocytes, contain as the active ingredient compds. having an inhibitory effect on metal-containing enzymes (in particular, zinc-containing enzymes). These inhibitors inhibit the process of the invasion into erythrocytes and proliferation therein of plasmodium after the infection, and the process of the invasion into erythrocytes and proliferation therein of the merozoites thus formed, thereby achieving preventive and therapeutic

effects on the onset of malaria. Claimed compds. include [4-(N-hydroxyamino)-2(R)-isobutyl-3(S)-methylsuccinyl]-L-phenylglycine-N-methylamide and N-[2,2-dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide.

IT **351316-90-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxamic acids as inhibitors for plasmodial invasion into erythrocytes)

RN 351316-90-0 HCAPLUS
CN Glycinamide, N-[(2R)-2-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 21 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:142139 HCAPLUS
DOCUMENT NUMBER: 134:188234
TITLE: Metalloproteinase inhibitors containing hydroxamic acids
INVENTOR(S): Fujisawa, Tetsunori; Kotake, Shinjiro; Hongo, Kazuya; Ito, Hajime; Otani, Miwa; Yasuda, Junko; Morikawa, Tadanori
PATENT ASSIGNEE(S): Fuji Pharmaceutical Industries Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 68 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001055327	A2	20010227	JP 2000-173115	20000609

PRIORITY APPLN. INFO.: JP 1999-165675 A 19990611
OTHER SOURCE(S): MARPAT 134:188234

AB The inhibitors, useful for treatment of ulcerative colitis, autoimmune diseases, osteoarthritis, malignant tumor, psoriasis, and diabetes mellitus, contain R1ONR2COCHR3CHR4CONHCH(CR6R7R8)COR5 [I; R1 = H, protective group; R2 = H, protective group; R3, R7, R8 = H, OH, (un)substituted alkyl, (un)substituted aralkyl; R4 = (un)substituted alkyl, (un)substituted aralkyl; R5 = OR9, NR10R11; R9 = H, (un)substituted alkyl, (un)substituted aralkyl, etc.; R10, R11 = H, (un)substituted (cyclo)alkyl, heterocyclyl, etc.; R6 = H, OH, amino, etc.], their salts, or solvates. I show good bioavailability. I monoacetate [R1 = R2 = R7 =

R8 = H, R3 = Me, R4 = iso-Bu, R5 = NHMe, R6 = (CH2)2NHC(:NH)NH2] (preparation given) in vitro inhibited collagenase (MMP-1) with IC50 of 5 nM. Formulation examples are given.

IT **228260-68-2P 228261-56-1P 328066-14-4P 328066-18-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acids as metalloproteinase inhibitors)

RN 228260-68-2 HCAPLUS
CN Butanediamide, N1-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N4-hydroxy-2-(2-methylpropyl)-3-(3-phenylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228260-67-1
CMF C29 H50 N6 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 228261-56-1 HCAPLUS
CN Butanediamide, 2-[3-(4-aminophenyl)propyl]-N4-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N1-hydroxy-3-(2-methylpropyl)-, (3R)-, triacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-55-0
CMF C29 H51 N7 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 328066-14-4 HCAPLUS
CN Butanediamide, N1-[(1S)-1-[[4-(aminomethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-N4-hydroxy-2,3-bis(2-methylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-50-5
CMF C26 H45 N5 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 328066-18-8 HCAPLUS
CN Butanediamide, N1-[(1S)-2-[[2-(dimethylamino)ethyl]amino]-1-[[4-[[(1-iminoethyl)amino]methyl]phenyl]methyl]-2-oxoethyl]-N4-hydroxy-2,3-bis(2-methylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 328066-17-7
CMF C28 H48 N6 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



L20 ANSWER 22 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:78256 HCAPLUS
DOCUMENT NUMBER: 134:136715
TITLE: Solutions and methods for inhibition of pain, inflammation and cartilage degradation
INVENTOR(S): Demopulos, Gregory A.; Palmer, Pamela P.; Herz, Jeffrey M.
PATENT ASSIGNEE(S): Omeros Medical Systems, Inc., USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 14
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007067	A2	20010201	WO 2000-US19864	20000721
WO 2001007067	A3	20010329		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1200127	A2	20020502	EP 2000-947581	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505427	T2	20030212	JP 2001-511950	20000721
US 2003235589	A1	20031225	US 2003-356649	20030131

PRIORITY APPLN. INFO.:

US 1999-144904P	P	19990721
US 1998-105026P	P	19981020
US 1998-107256P	P	19981105
WO 1999-US24625	A2	19991020
WO 1999-US26330	A2	19991105
WO 2000-US19864	W	20000721
US 2001-839633	A2	20010420
US 2002-31546	A2	20020118
US 2002-353552P	P	20020201

AB Methods and solns. for inhibiting a variety of pain and inflammation processes at wounds from general surgical procedures including arthroscopic procedures, and for inhibiting cartilage degradation are disclosed. The solns. preferably include multiple pain and inflammation inhibitory at dilute concentration in a physiol. carrier, such as saline or lactated Ringer's solution The solution may be applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, i.m., s.c. or i.v. application of larger doses of the agents. Alternatively, for combinations of cartilage degradation inhibitors, the solns. may be injected directly into the joint. An irrigation solution for arthroscopy was prepared containing SB203580 (MAP kinase inhibitor) 200, U-24522 (matrix metalloproteinase inhibitor) 200, and TGF-β2 200 nM.

IT **106314-87-8**, U-24522
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solns. and methods for inhibition of pain, inflammation and cartilage degradation)

RN 106314-87-8 HCAPLUS

CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 23 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:861771 HCAPLUS
DOCUMENT NUMBER: 134:14908
TITLE: In vitro cell culture device including cartilage and methods of using the same
INVENTOR(S): Hicks, Wesley L., Jr.
PATENT ASSIGNEE(S): Research Foundation of State University of New York, USA
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073417	A1	20001207	WO 2000-US14526	20000526
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6312952	B1	20011106	US 2000-579805	20000526
US 2002009806	A1	20020124	US 2001-953990	20010918
US 6465205	B2	20021015		

PRIORITY APPLN. INFO.: US 1999-136610P P 19990527
US 2000-579805 A3 20000526

AB The present invention relates to an in vitro cell culture device which includes a vessel comprising an inner surface, a layer of cartilage disposed on at least a portion of said inner surface, the layer of cartilage including a plurality of chondrocytes in an extracellular matrix, and a growth medium in the vessel, the layer of cartilage being bathed in the growth medium. Also disclosed is a composite cell culture prepared from the in vitro cell culture device, the composite cell culture includes a first layer including chondrocytes in an extracellular matrix, a second layer disposed on the first layer and including type I collagen, and a third layer disposed on the second layer and including cells at least partially covering the second layer. Further aspects of the present invention relate to methods of preparing an in vitro composite cell culture, methods of screening putative therapeutic agents for activity in promoting re-epithelialization of cartilaginous tissues, and methods of screening putative therapeutic agents for activity in inhibiting growth factors or

proteinases.

IT **142880-36-2**, GM6001
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(In vitro cell culture device including cartilage and methods of using same)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 24 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:592569 HCAPLUS
DOCUMENT NUMBER: 133:183019
TITLE: Connective tissue softening with matrix metalloproteinase inhibitors
INVENTOR(S): Ferguson, Mark William James
PATENT ASSIGNEE(S): Victoria University of Manchester, UK
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048617	A2	20000824	WO 2000-GB474	20000214
WO 2000048617	A3	20010208		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1152757	A2	20011114	EP 2000-903808	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537268	T2	20021105	JP 2000-599407	20000214
US 6455569	B1	20020924	US 2001-913713	20010817

PRIORITY APPLN. INFO.: GB 1999-3598 A 19990218
WO 2000-GB474 W 20000214

AB Matrix Metalloproteinase Inhibitors are used in the prevention or treatment of connective tissue softening and also for the maintenance of sutures in such connective tissues. The connective tissue may be a tendon, ligament or cartilage. Example inhibitors are batimastat or galardin.

IT **142880-36-2**, Galardin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(connective tissue softening with matrix metalloproteinase inhibitors)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 25 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:68329 HCAPLUS
DOCUMENT NUMBER: 132:117536
TITLE: Hydroxamic acid derivatives as novel remedies for allergic diseases
INVENTOR(S): Igeta, Katsuhiro; Tobetto, Kenji; Saiki, Ikuo; Odake, Shinjiro; Fujisawa, Tetsunori; Matsuo, Tetsu; Oku, Tohru
PATENT ASSIGNEE(S): Fuji Yakuhin Kogyo Kabushiki Kaisha, Japan; Maruho Co., Ltd.
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000003703	A1	20000127	WO 1999-JP3851	19990716
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337859	AA	20000127	CA 1999-2337859	19990716

AU 9946531 A1 20000207 AU 1999-46531 19990716
EP 1101492 A1 20010523 EP 1999-929875 19990716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRIORITY APPLN. INFO.: JP 1998-218662 A 19980717
WO 1999-JP3851 W 19990716

AB Drugs characterized by containing hydroxamic acid derivs. as the active ingredient which are efficacious in treating and/or preventing allergies, in particular, type I and/or type II allergies, etc. These drugs exert therapeutic and/or preventive effects on inflammation, rhinitis, conjunctivitis, bronchial asthma, atopic dermatitis (dermatitis, enteritis, etc.) and allergic digestive inflammation. Use of these drugs achieves the effects of: (A) inhibiting the proliferation of colonies of blood cells (lymphocytes, etc.) in an affected part; and/or (B) relieving inflammation caused by the migration, infiltration, accumulation, etc. of blood cells (lymphocytes, etc.) into an affected part; and/or (C) regulating the pathophysiol. functions of cells such as blood cells (lymphocytes, etc.), Langerhans cells and dendritic cells; and/or (D) regulating the production of antibodies, in particular, IgE in the plasma, thus being useful in treating and/or preventing diseases or pathol. conditions in the affected parts.

IT **228260-68-2P 228261-52-7P 228261-56-1P**
256412-42-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydroxamic acid derivs. as novel remedies for allergic diseases)

RN 228260-68-2 HCAPLUS

CN Butanediamide, N1-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N4-hydroxy-2-(2-methylpropyl)-3-(3-phenylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228260-67-1
CMF C29 H50 N6 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 228261-52-7 HCAPLUS
CN Butanediamide, N-[(1S)-2-[[2-(dimethylamino)ethyl]amino]-1-[[4-[[(1-iminoethyl)imino]methyl]phenyl]methyl]-2-oxoethyl]-N'-hydroxy-2,3-bis(2-methylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-51-6
CMF C28 H46 N6 O4

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 228261-56-1 HCAPLUS
CN Butanediamide, 2-[3-(4-aminophenyl)propyl]-N4-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N1-hydroxy-3-(2-methylpropyl)-, (3R)-, triacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-55-0
CMF C29 H51 N7 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 256412-42-7 HCAPLUS
CN Butanediamide, N-[(1S)-1-[[4-(aminomethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-N'-hydroxy-2,3-bis(2-methylpropyl)-, (2R,3S)-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 256412-41-6
CMF C26 H45 N5 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 26 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:15004 HCAPLUS
DOCUMENT NUMBER: 132:73666
TITLE: Ophthalmic uses of PPAR-γ agonists and antagonists
INVENTOR(S): Pershadsingh, Harrihar A.; Levy, Daniel E.
PATENT ASSIGNEE(S): Photogenesis, Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000000194	A1	20000106	WO 1999-US14262	19990625
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9947134	A1	20000117	AU 1999-47134	19990625
US 6316465	B1	20011113	US 1999-342381	19990628

PRIORITY APPLN. INFO.: US 1998-90937P P 19980627
US 1998-90937 P 19980627
WO 1999-US14262 W 19990625

OTHER SOURCE(S): MARPAT 132:73666

AB Methods are disclosed for treating diseases of ocular tissues expressing the nuclear receptor PPAR-γ, by inhibiting the inflammatory response, the neovascularization and angiogenesis, and programmed cell death (apoptosis) in these target tissues, comprising administering to a human or animal in need of treatment an effective amount of a compound that modifies the activity of PPAR-γ, or a pharmaceutically acceptable salt or solvate thereof. Novel compds. and methods for their synthesis are provided.

IT **253587-93-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ophthalmic uses of PPAR-γ agonists and antagonists)

RN 253587-93-8 HCAPLUS
CN Butanediamide, N4-[(1S)-1-[[[2-[[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)carbonyl][2-[4-[[(5R)-2,4-dioxo-5-thiazolidinyl]methyl]phenoxy]ethyl]amino]ethyl]amino]carbonyl]-2,2-dimethylpropyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 27 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:583142 HCAPLUS
DOCUMENT NUMBER: 131:223493
TITLE: Peptide derivatives for prevention or treatment of connective tissue disease
INVENTOR(S): Matsuo, Konomi; Yamamoto, Minoru; Ikeda, Shoji
PATENT ASSIGNEE(S): Kanebo, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11246436	A2	19990914	JP 1998-71445	19980304

PRIORITY APPLN. INFO.: JP 1998-71445 19980304
OTHER SOURCE(S): MARPAT 131:223493

AB Peptide derivs. such as [4-(N-hydroxyamino)-2-[R]-isobutylsuccinyl]-L-phenylalanyl-L-alaninal [prepns. given] as matrix metalloprotease and cathepsin for prevention or treatment of connective tissue disease are claimed. The compds. lowered the urinary hydroxyproline excretion in mice with osteoporosis. Capsules were formulated containing [4-(N-hydroxyamino)-2-[R]-isobutylsuccinyl]-L-phenylalanyl-L-alaninal 100, lactose 35, corn starch 60 and magnesium stearate 5 weight parts.

IT **244021-29-2P 244021-30-5P 244021-31-6P**
244021-32-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(peptide derivs. for prevention or treatment of connective tissue disease)

RN 244021-29-2 HCAPLUS
CN L-Alaninamide, N-[(2R)-4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl-N-methoxy-N-methyl-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244021-30-5 HCAPLUS
CN L-Alaninamide, N-[(2R)-4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-leucyl-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244021-31-6 HCAPLUS
CN L-Leucinamide, N-[(2R)-4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244021-32-7 HCAPLUS
CN Glycinamide, N-[(2R)-4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 28 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:511239 HCAPLUS
DOCUMENT NUMBER: 131:155326
TITLE: Crystalline TNF-α-converting enzyme and uses thereof
INVENTOR(S): Black, Roy A.; Paxton, Raymond James; Bode, Wolfram; Maskos, Klaus; Fernandez-Catalan, Carlos; Chen, James Ming; Levin, Jeremy Ian
PATENT ASSIGNEE(S): Immunex Corporation, USA; Max-Planck-Institute for Biochemistry; American Home Products Corporation
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940182	A2	19990812	WO 1999-US2185	19990203
WO 9940182	A3	19991007		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2319040	AA	19990812	CA 1999-2319040	19990203
AU 9925740	A1	19990823	AU 1999-25740	19990203
ZA 9900851	A	19990825	ZA 1999-851	19990203
EP 1053304	A2	20001122	EP 1999-905615	19990203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 505959	A	20030530	NZ 1999-505959	19990203
JP 2004503202	T2	20040205	JP 2000-530596	19990203
US 2002081692	A1	20020627	US 1999-244984	19990204
NO 2000003687	A	20000919	NO 2000-3687	20000718
US 2003004651	A1	20030102	US 2001-57321	20010924

PRIORITY APPLN. INFO.:

US 1998-73709P	P	19980204
US 1998-50083	A1	19980330
US 1999-117476P	P	19990127
US 1998-135499P	P	19980330
WO 1999-US2185	W	19990203
US 1999-244984	A3	19990204
US 2000-611722	B1	20000706

AB A tumor necrosis factor-α converting enzyme (TACE) is produced,

purified, and crystallized The three-dimensional coordinates of the crystal are obtained by x-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying TACE. The coordinates are also used in designing, screening, and developing compds. that associate with TACE.

IT **187034-31-7**
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(crystal structure of TNF-α-converting enzyme and its uses)

RN 187034-31-7 HCAPLUS

CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methyl-L-valyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 29 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:421569 HCAPLUS
DOCUMENT NUMBER: 131:68144
TITLE: Angiotensin-converting enzyme inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure
INVENTOR(S): Peterson, Joseph Thomas, Jr.; Pressler, Milton Lethan
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932150	A1	19990701	WO 1998-US23993	19981110
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2305436	AA	19990701	CA 1998-2305436	19981110
AU 9915220	A1	19990712	AU 1999-15220	19981110
AU 751701	B2	20020822		
BR 9814422	A	20001010	BR 1998-14422	19981110
EP 1047450	A1	20001102	EP 1998-959416	19981110
EP 1047450	B1	20021002		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2001526245	T2	20011218	JP 2000-525140		19981110
NZ 503962	A	20020328	NZ 1998-503962		19981110
AT 225187	E	20021015	AT 1998-959416		19981110
ES 2184340	T3	20030401	ES 1998-959416		19981110
ZA 9811794	A	19990629	ZA 1998-11794		19981222
US 6133304	A	20001017	US 2000-485253		20000207
MX 200003736	A	20001020	MX 2000-3736		20000417
NO 2000003256	A	20000622	NO 2000-3256		20000622
PRIORITY APPLN. INFO.:			US 1997-68594P	P	19971223
			WO 1998-US23993	W	19981110

OTHER SOURCE(S): MARPAT 131:68144

AB Combinations of ACE inhibitors and MMP inhibitors are useful to slow and reverse the process of fibrosis, ventricular dilation, and heart failure in mammals.

IT **106314-87-8**, U24522 **142880-36-2**, Galardin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACE inhibitor-matrix metalloproteinase inhibitor combinations for treatment of fibrosis, ventricular dilation, and heart failure)

RN 106314-87-8 HCAPLUS

CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 30 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:404921 HCAPLUS
DOCUMENT NUMBER: 131:73975
TITLE: Preparation of N-[4-(hydroxyamino)succinyl]amino acid amide derivatives as metalloproteinase inhibitors
INVENTOR(S): Fujisawa, Tetsunori; Odake, Shinjiro; Hongo, Kazuya; Ohtani, Miwa; Yasuda, Junko; Morikawa, Tadanori
PATENT ASSIGNEE(S): Fuji Yakuhin Kogyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9931052	A1	19990624	WO 1998-JP5620	19981211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2313649	AA	19990624	CA 1998-2313649	19981211
AU 9915066	A1	19990705	AU 1999-15066	19981211
AU 753017	B2	20021003		
JP 2000086611	A2	20000328	JP 1998-374945	19981211
EP 1038864	A1	20000927	EP 1998-959181	19981211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813554	A	20010724	BR 1998-13554	19981211
RU 2200154	C2	20030310	RU 2000-118320	19981211

PRIORITY APPLN. INFO.: JP 1997-362364 A 19971212
JP 1998-218676 A 19980717
WO 1998-JP5620 W 19981211

OTHER SOURCE(S): MARPAT 131:73975

AB Claimed are compds. represented by general formula R1ONR2COCHR3CHR4CONHCH(CR7R8R9)CONR5R6 or salts thereof [I; wherein R1 represents hydrogen, (un)substituted aralkyl, tri-substituted silyl, tetrahydropyranyl, (un)substituted aralkyloxycarbonyl, (un)substituted alkyl, or a hydroxy-protective group; R2 represents hydrogen, (un)substituted aralkyloxycarbonyl, (un)substituted alkyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, or an amino-protective group; R3, R7 and R8 represent each hydrogen, hydroxy, (un)substituted alkyl, or (un)substituted aralkyl; R4 represents (un)substituted alkyl or (un)substituted arylalkyl; R5 and R6 are the same or different and each represents hydrogen, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, or an amino-protective group; or NR5R6 represents an (un)substituted heterocyclyl; and R9 represents hydrogen, hydroxy, amino, or -X-Y; wherein X represents (un)substituted C1-6 alkylene or (un)substituted phenylene; Y represents -A-B; wherein A represents (un)substituted C1-6 alkylene, O, S, NH, or (un)substituted C1-6 alkylene imino; B represents hydrogen, amino, amidino, acylimidoyl, (un)substituted imidazolyl, (un)protected bisphosphonomethyl, or (un)protected bisphosphonohydroxymethyl]. Also claimed are (i) medicinal and/or veterinary compns. containing I, in particular, metalloproteinase

inhibitors inhibiting matrix metalloproteinases and tumor necrosis factor-α (TNF-α) convertase and (ii) the use of I for the prevention or treatment of tissue degenerative diseases. These compds. have not only a high metalloproteinase inhibitory activity but also remarkably improved medicinal applicability (in vivo) (oral absorbability, etc.) and biol. activities and thus being useful as drugs. Thus, treatment of Nα-tert-butoxycarbonyl-Nε,Nε-bis(benzyloxycarbonyl)-L-arginine-N-methylamide with 4 N HCl/EtOAc followed by condensation with 4-(p-phthalimidomethylphenyl)-3(RS)-tert-butoxycarbonyl-2(R)-isobutylbutyric acid, treatment with CF3CO2H, condensation with O-benzylhydroxylamine hydrochloride, and hydrogenolysis over 5% Pd-C gave Nα-[4-(hydroxyamino)-2(R)-isobutyl-3(RS)-(p-phthalimidomethylbenzyl)succinyl]-L-arginine N-methylamine monoacetic acid salt (II). II showed IC50 of 2 nM against Matrix metalloproteinase MMP-3. Pharmaceutical formulations containing I, e.g. an ointment containing II, were described.

IT **228260-68-2P 228261-50-5P 228261-52-7P 228261-56-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[4-(hydroxyamino)succinyl]amino acid amide derivs. as metalloproteinase tumor necrosis factor-α convertase inhibitors)

RN 228260-68-2 HCAPLUS

CN Butanediamide, N1-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N4-hydroxy-2-(2-methylpropyl)-3-(3-phenylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228260-67-1
CMF C29 H50 N6 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 228261-50-5 HCAPLUS
CN Butanediamide, N-[(1S)-1-[[4-(aminomethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-N'-hydroxy-2,3-bis(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228261-52-7 HCAPLUS
CN Butanediamide, N-[(1S)-2-[[2-(dimethylamino)ethyl]amino]-1-[[4-[[(1-iminoethyl)imino]methyl]phenyl]methyl]-2-oxoethyl]-N'-hydroxy-2,3-bis(2-methylpropyl)-, (2R)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-51-6
CMF C28 H46 N6 O4

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 228261-56-1 HCAPLUS
CN Butanediamide, 2-[3-(4-aminophenyl)propyl]-N4-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-[(1-iminoethyl)amino]pentyl]-N1-hydroxy-3-(2-methylpropyl)-, (3R)-, triacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 228261-55-0
CMF C29 H51 N7 O4

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 31 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:231223 HCAPLUS
DOCUMENT NUMBER: 130:252675
TITLE: Process for the preparation of N-acyl-L-tryptophan carboxamide derivatives as synthetic matrix metalloprotease inhibitors
INVENTOR(S): Levy, Daniel E.; Grobelny, Damian; Tang, Cho; Holme, Kevin R.; Galardy, Richard E.; Schultz, Gregory S.; Nematalia, Asaad; Musser, John H.
PATENT ASSIGNEE(S): Glycomed Incorporated, USA; The University of Florida
SOURCE: U.S., 46 pp., Cont.-in-part of U.S. Ser. No. 44,324. CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5892112	A	19990406	US 1994-184727	19940121
US 5114953	A	19920519	US 1990-616021	19901121
US 5183900	A	19930202	US 1990-615798	19901121
US 5189178	A	19930223	US 1991-747752	19910820
US 5239078	A	19930824	US 1991-747751	19910820
CA 2096225	AA	19930221	CA 1991-2096225	19911121
US 5268384	A	19931207	US 1992-817039	19920107
US 5270326	A	19931214	US 1992-881630	19920512
US 5696147	A	19971209	US 1993-161786	19931203
US 5773438	A	19980630	US 1994-464927	19940605
CA 2158760	AA	19950727	CA 1995-2158760	19950120
WO 9519965	A1	19950727	WO 1995-US783	19950120
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9516049	A1	19950808	AU 1995-16049	19950120
EP 690841	A1	19960110	EP 1995-908086	19950120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501183	T2	19970204	JP 1995-519668	19950120
AU 9883118	A1	19990128	AU 1998-83118	19980904
AU 9910003	A1	19990304	AU 1999-10003	19990104

PRIORITY APPLN. INFO.:

US 1990-616021	A1	19901120
US 1990-615798	A2	19901121
US 1991-747751	A1	19910820
US 1991-747752	A2	19910820
US 1992-817039	A2	19920107
US 1992-881630	A1	19920512
US 1993-44324	A2	19930407
US 1990-477751	B2	19900209
US 1991-615798	A	19911121
US 1994-184727	A3	19940121
AU 1994-65542	A3	19940401
AU 1995-16049	A3	19950120
WO 1995-US783	W	19950120

OTHER SOURCE(S): MARPAT 130:252675

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for the preparation of N-acyl-L-tryptophan derivs. I [R1 = H, alkyl; R2 = H, alkyl, NHZ; Z = R11, COR11, CO2R11; R11 = alkyl; R1R2 = (CH2)p; p = 3-5; R3 = H, C1-4 alkyl; R4 = Me, fused or conjugated, (un)substituted bicycloarylmethylene; n = 0-2; X = OR5, NHR5, NR5R5, NH(CH2)q, M; R5 = independently H, (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl; q = 1-8; M = amino acid residue, amino acid amide residue, cyclic amino, heterocyclic amino; R6 = H, lower alkyl; R7 = H, lower alkyl, acyl] as synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock. Thus, benzyl 4-methyl-2-oxopentanoate underwent Wittig reaction with Ph3P:CHCO2Me (100%), hydrogenation of the formed unsatd. diester (86%), peptide coupling of the obtained monoacid with H-Trp-NHMe.HCl and separation of diastereomers (83%), and reaction with NH2OH (56% and 72%), to give isomeric title compds. II and III. II inhibited 72 kD gelatinase with Ki

= 0.26 nM and 92 kD gelatinase with Ki = 0.22 nM. Procedures using II for the inhibition of angiogenesis, treatment of psoriasis, treatment of chronic dermal wounds, treatment of thioglycollate-induced peritonitis, antimetastasis activity, treatment of hypovolumic shock, and antirestenotic activity are also given.

IT **142880-36-2P 142880-37-3P 142880-75-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(process for preparation of N-acyl-L-tryptophan carboxamide derivs. as synthetic matrix metalloprotease inhibitors)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-75-9 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142880-38-4P 142880-62-4P 162550-05-2P**
171347-80-1P 171347-81-2P 171347-82-3P
171347-83-4P 171347-85-6P 200959-08-6P
221622-65-7P 221622-69-1P 221622-71-5P
221622-75-9P 221622-77-1P 221622-82-8P
221622-83-9P 221622-86-2P 221622-94-2P
221622-97-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of N-acyl-L-tryptophan carboxamide derivs. as synthetic matrix metalloprotease inhibitors)

RN 142880-38-4 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-62-4 HCAPLUS

CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162550-05-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-80-1 HCAPLUS
CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-81-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-82-3 HCAPLUS
CN Butanediamide, N4-[(4-fluorophenyl)methyl]-N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-83-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N4-(methoxymethyl)-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-85-6 HCAPLUS
CN Glycine, N-hydroxy-N-[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]- (9CI) (CA INDEX NAME)

Searched by P. Ruppel

Absolute stereochemistry.



RN 200959-08-6 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-65-7 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-69-1 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by P. Ruppel



RN 221622-71-5 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-75-9 HCAPLUS
CN Butanediamide, N1-[(1S)-2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-77-1 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-82-8 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-83-9 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-86-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-94-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-3-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-97-5 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [hydroxy[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **171347-98-1P 171348-01-9P 171348-03-1P**
171348-04-2P 221622-96-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for preparation of N-acyl-L-tryptophan carboxamide derivs. as synthetic matrix metalloprotease inhibitors)

RN 171347-98-1 HCAPLUS
CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-01-9 HCAPLUS
CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-N4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-03-1 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl](phenylmethoxy)amino]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-04-2 HCAPLUS
CN Glycine, N-[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]-N-(phenylmethoxy)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221622-96-4 HCAPLUS
CN Butanediamide, N4-[(4-fluorophenyl)methyl]-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 32 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:77667 HCAPLUS
DOCUMENT NUMBER: 130:136300
TITLE: Methods for the preparation of artificial cellular tissue using matrix metalloproteinase inhibitors
INVENTOR(S): Wolowacz, Richard; Wolowacz, Sorrel; Sheridan, Julie Marie
PATENT ASSIGNEE(S): Smith & Nephew PLC, UK
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9903979	A1	19990128	WO 1998-GB2147	19980717
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9884514	A1	19990210	AU 1998-84514	19980717
PRIORITY APPLN. INFO.:			GB 1997-14936	19970717
			WO 1998-GB2147	19980717

AB There is disclosed the use of matrix metalloproteinase (MMP) inhibitors, e.g. collagenase, stromelysin, or gelatinase inhibitors in the production of tissue equivalent The inhibitors are used in particular to inhibit MMPs present in animal serum used in the production technique, thereby increasing collagen deposition. Tissue culture media and extracted animal serum containing a supplemented MMP inhibitor are also disclosed. Polylactic acid yarns seeded with fibroblasts of human fetal foreskin were cultured with media supplemented with doxycycline. Increased collagen content was observed in

the test samples compared to control (lacking doxycycline).

IT **142880-36-2**, Galardin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(as inhibitor; matrix metalloproteinase inhibitors in preparation of artificial cellular tissue)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 33 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:786799 HCAPLUS
Correction of: 1998:682232

DOCUMENT NUMBER: 129:343729
Correction of: 129:290443

TITLE: Preparation of Hydroxamic acids substituted by heterocycles as TNF production inhibitors

INVENTOR(S): Bird, Thomas Geoffrey Colerick

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca Pharma S.A.

SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843959	A1	19981008	WO 1998-GB910	19980325
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868432	A1	19981022	AU 1998-68432	19980325
EP 971895	A1	20000119	EP 1998-913907	19980325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

JP 2001518090	T2	20011009	JP 1998-541286		19980325
US 6251913	B1	20010626	US 1999-381836		19990924
US 2002040002	A1	20020404	US 2001-814119		20010322
PRIORITY APPLN. INFO.:			EP 1997-400725	A	19970328
			WO 1998-GB910	A	19980325
			US 1999-381836	A1	19990924

OTHER SOURCE(S): MARPAT 129:343729

GI



I

AB Title compds. [I; wherein: n is 1 to 6; Het is a nitrogen containing ring fused to the benzene ring on two adjacent carbon atoms to form a bicyclic ring system which ring system may be optionally substituted; R1 is hydrogen, C1-8alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC1-6alkyl, heteroarylC1-6alkyl, heterocyclylC1-6alkyl or C3-8cycloalkylC1-6alkyl; R2 is C1-6alkyl, C2-6alkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or the side-chain of a naturally occurring amino acid; R3 is hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-8cycloalkenyl, arylC1-6alkyl, heteroarylC1-6alkyl or heterocyclylC1-6alkyl; R4 is hydrogen or C1-6alkyl; or R3 and R4 together with the nitrogen atom to which they are joined form a heterocyclic ring; wherein any group or ring, in R1-R4, is optionally substituted], stereoisomers, pharmaceutically acceptable salts, and in vivo hydrolyzable esters thereof, are prepared and described as inhibitors of TNF production inhibitors.

IT **215606-12-5P 215606-21-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acids substituted by heterocycles as TNF production inhibitors)

RN 215606-12-5 HCAPLUS

CN Butanediamide, 2-[(1,2-dihydro-1-methyl-2-oxo-6-quinolinyl)methoxy]-N4-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2,2-dimethylpropyl]-N1-hydroxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 215606-21-6 HCAPLUS
CN Butanediamide, N1-[(1S)-1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2,2-dimethylpropyl]-N4-hydroxy-2-(2-methylpropyl)-3-(8-quinolinylmethoxy)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 34 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:709044 HCAPLUS
DOCUMENT NUMBER: 129:331045
TITLE: Preparation of amino acid derivatives which inhibit extracellular matrix metalloproteinase and TNF-α release
INVENTOR(S): Jeanpetit, Christian; Pringent, Didier; Settembre, Pierre-Andre; Trancart, Marie-Michele
PATENT ASSIGNEE(S): Laboratoires Jacques Logeais, Fr.
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9847863	A1	19981029	WO 1998-FR801	19980421

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG

FR 2762315	A1	19981023	FR 1997-4971		19970422
FR 2762315	B1	19990528			
AU 9875346	A1	19981113	AU 1998-75346		19980421
EP 977730	A1	20000209	EP 1998-922850		19980421
EP 977730	B1	20030312			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
AT 234278	E	20030315	AT 1998-922850		19980421
ES 2194319	T3	20031116	ES 1998-922850		19980421
ZA 9803390	A	19990209	ZA 1998-3390		19980422
US 6344457	B1	20020205	US 1999-403037		19991217
PRIORITY APPLN. INFO.:			FR 1997-4971	A	19970422
			WO 1998-FR801	W	19980421

OTHER SOURCE(S): MARPAT 129:331045

AB Amino acid derivs. YCHR2CR1(OH)CO-AA-R3 [Y = CONHOH, SH, N(OH)CHO, P(O)R5OR4, where R4 = H, alkyl; R5 = (un)substituted 1,8-naphthalenedicarboximido; R1 = alkyl or cycloalkyl chain optionally containing a heteroatom, (un)substituted phenoxyalkyl or phenylalkyl, heteroarylalkyl; R2 = H, alkyl, alkylidene, OH, alkoxy, benzyloxy, hydroxymethyl, alkoxymethyl, arylalkyl, aryloxymethyl, arylthiomethyl, heteroarylthiomethyl, phthalimidoalkyl, alkoxycarbonylmethyl, benzyloxycarbonylmethyl, acetylmethyl; AA represents an amino acid residue or sequence; R3 = substituted alkylamino] were prepared as inhibitors of extracellular matrix metalloproteinase and TNF-α release. Thus, (S,S)-HONHCOCHMeC(OH)(Bu-i)CO-Tyr(Me)-NHMe, prepared by a multistep procedure, showed CI50 = 1 μM for inhibition of TNF.

IT **215310-95-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. which inhibit extracellular matrix metalloproteinase and TNF-α release)

RN 215310-95-5 HCAPLUS

CN Butanediamide, N4,2-dihydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-3-methyl-2-(2-methylpropyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 35 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:424117 HCAPLUS
DOCUMENT NUMBER: 129:113523
TITLE: Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
INVENTOR(S): Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David
PATENT ASSIGNEE(S): Warner-Lambert Co., USA; Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826773	A1	19980625	WO 1997-US21532	19971121
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9877353	A1	19980715	AU 1998-77353	19971121
AU 737117	B2	20010809		
EP 946166	A1	19991006	EP 1997-949584	19971121
EP 946166	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9714142	A	20000229	BR 1997-14142	19971121
JP 2001507342	T2	20010605	JP 1998-527715	19971121
NZ 334925	A	20010629	NZ 1997-334925	19971121
EP 1366765	A1	20031203	EP 2003-18081	19971121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
AT 259640	E	20040315	AT 1997-949584	19971121
ZA 9711279	A	19980623	ZA 1997-11279	19971215
US 6340709	B1	20020122	US 1999-269123	19990319

PRIORITY APPLN. INFO.: US 1996-32753P P 19961217
EP 1997-949584 A3 19971121
WO 1997-US21532 W 19971121
OTHER SOURCE(S): MARPAT 129:113523
AB Matrix metalloproteinase inhibitors 4-RC6H4SO2NHCHR1COR2 [R = (un)substituted Ph; R1 = alkyl, phenylalkyl, phenyl; R2 = OH, alkoxy, NHOH] and 4-RC6H4C(:NR3)CR4R5CR6R7COR8 [R3 = (un)substituted OH, NH2; R4-R7 = H, F, (un)substituted alkyl; R8 = OH, SH] are useful for preventing and treating neurol. disorders, especially Alzheimer's, huntington's, and Parkinson's diease and amyotropic lateral sclerosis, and in promoting wound healing. IC50 for matrix metalloproteinase inhibition are reported for a number of compds. Formulations containing (R)-4-(4-NCC6H4)C6H4SO2NHCH(CO2H)CH2Ph, (S)-4-(4-H2NC6H4)C6H4SO2NHCH(CO2H)CH2C6H4OEt-3, and 4-(4-BrC6H4)C6H4SO2NHCH(CO2H)CHMe2 are reported.
IT **106314-87-8**, U24522 **142880-36-2**, Galardin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of matrix metalloproteinase inhibitors for treating neurol. disorders and promoting wound healing)

RN 106314-87-8 HCAPLUS
CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 36 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:402296 HCAPLUS
DOCUMENT NUMBER: 129:76499
TITLE: Method for treating and preventing heart failure and ventricular dilation
INVENTOR(S): Peterson, Joseph T., Jr.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9825597	A2	19980618	WO 1997-US21934	19971202	
WO 9825597	A3	20001012			
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9855906	A1	19980703	AU 1998-55906	19971202	
AU 741768	B2	20011206			
BR 9714385	A	20000516	BR 1997-14385	19971202	
EP 1028716	A1	20000823	EP 1997-952246	19971202	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
NZ 334897	A	20010223	NZ 1997-334897	19971202	
JP 2001526631	T2	20011218	JP 1998-526758	19971202	
ZA 9711004	A	19981005	ZA 1997-11004	19971208	
US 5948780	A	19990907	US 1997-987167	19971208	
NO 9902769	A	19990809	NO 1999-2769	19990608	
PRIORITY APPLN. INFO.:			US 1996-32631P	P 19961209	
			WO 1997-US21934	W 19971202	

OTHER SOURCE(S): MARPAT 129:76499

AB Matrix metalloproteinase inhibitors are useful for preventing and treating heart failure, and ventricular dilation in mammals. Thus, 2-(4'-bromobiphenyl-4-sulfonylamino)-3-methylbutyric acid was effective in protecting pigs in the pacing-induced heart failure model.

IT **106314-87-8**, U24522 **142880-36-2**, Galardin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of matrix metalloproteinase inhibitors in treating heart failure and ventricular dilation)

RN 106314-87-8 HCAPLUS

CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 37 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:394241 HCAPLUS
DOCUMENT NUMBER: 129:62957
TITLE: Inhibitors of invasive tissue remodelling for use as contraceptives and antitumor agents
INVENTOR(S): Lund, Leif Roge; Dano, Keld; Stephens, Ross; Brunner, Nils; Solberg, Helene; Holst-Hansen, Claus; Nielsen, John Romer
PATENT ASSIGNEE(S): Fonden Til Fremme Af Eksperimentel Cancerforskning, Den.; Dano, Keld; Stephens, Ross; Brunner, Nils; Solberg, Helene; Holst-Hansen, Claus; Nielsen, John Romer
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9824474	A1	19980611	WO 1997-DK555	19971208
W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9851876	A1	19980629	AU 1998-51876	19971208
EP 942746	A1	19990922	EP 1997-946746	19971208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2002099004	A1	20020725	US 2001-995636	20011129

PRIORITY APPLN. INFO.: DK 1996-1402 A 19961206
WO 1997-DK555 W 19971208
US 1999-319464 B1 19990827

AB The invention pertains to novel methods for preventing or arresting invasive remodelling in mammals by utilising a combination of in vivo inhibition of plasmin and in vivo inhibition of certain other proteolytic enzymes, notably metalloproteases. The method can e.g. be used as a novel alternative to current methods of contraception as well as antifungal and antibacterial treatment. The preferred embodiments relate to treatment

and prevention of neoplastic diseases by use of these combinations. Further, the invention relates to novel compns. which comprises a plasmin inhibitor in admixt. with an inhibitor of another proteolytic enzyme, preferably an inhibitor of a metalloprotease.

IT **142880-36-2**, Galardin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of invasive tissue remodelling for use as contraceptives and antitumor agents)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 38 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:219789 HCAPLUS
DOCUMENT NUMBER: 128:283080
TITLE: Preparation of hydroxamic acid derivatives for the suppression of TNF release and for treatment of autoimmune and inflammatory diseases
INVENTOR(S): Kottirsch, Georg; Neumann, Ulf
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Kottirsch, Georg; Neumann, Ulf
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814424	A1	19980409	WO 1997-EP5376	19970930
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9747068	A1	19980424	AU 1997-47068	19970930
AU 726065	B2	20001026		

EP 929517	A1	19990721	EP 1997-909339	19970930
EP 929517	B1	20020612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
BR 9712255	A	19990824	BR 1997-12255	19970930
CN 1232447	A	19991020	CN 1997-198511	19970930
CN 1101807	B	20030219		
JP 2000508338	T2	20000704	JP 1998-516236	19970930
JP 3444898	B2	20030908		
NZ 334908	A	20001027	NZ 1997-334908	19970930
AT 219050	E	20020615	AT 1997-909339	19970930
PT 929517	T	20021031	PT 1997-909339	19970930
ES 2178759	T3	20030101	ES 1997-909339	19970930
RU 2196131	C2	20030110	RU 1999-108792	19970930
ZA 9708800	A	19980402	ZA 1997-8800	19971001
NO 9901559	A	19990330	NO 1999-1559	19990330
KR 2000048811	A	20000725	KR 1999-702806	19990401
HK 1021637	A1	20030502	HK 2000-100370	20000120
US 2002038045	A1	20020328	US 2001-973255	20011009
US 6500983	B2	20021231		

PRIORITY APPLN. INFO.:	GB 1996-20572	A	19961002
	GB 1997-6667	A	19970402
	WO 1997-EP5376	W	19970930
	US 1999-269867	A1	19990401

OTHER SOURCE(S): MARPAT 128:283080

GI



I



II

AB 3-Aza-4-oxo-6-(oxymethyl)heptane 1,7-dioic acid (7-N-hydroxy)diamide and related compds. [I; R1 = A[O(CHR5)n]mOCH2; n = 1-4; m = 0-3; R5 = H, (substituted)alkyl, alkenyl, (substituted)aryl, etc.; A = H, alkyl, aryl, (aryl)alkyl, (aryl)carbonyl, (alkyl)carbonyl; R2 = alkyl, alkenyl, (substituted)cycloalkyl, (substituted)aryl; R3 = (substituted)alkyl, (substituted)aryl, indolylmethyl; R4 = Me, pyridyl, XY; X = morpholino, pyridyl, aryl; Y = C1-12 alkylene in which up to four of the methylene units are optionally replaced with CO, NH, SO2 or O] are claimed. For example, hydroxamic acid II is prepared from the starting materials of (E)-1,4-dibromobut-2-ene, diethylene glycol monomethyl ether, isocaproic acid, H-Phe-NHMe. The present compds. are useful in pharmaceuticals, such as in the suppression of TNF release (a range of IC50 values of 50 nM to 5 μM for title compds.), and in the treatment of inflammatory diseases (title compds. show dose dependent inhibition of collagenase at concns. below 10 nM).

IT **205806-93-5P 205806-95-7P 205807-08-5P 205807-28-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acids for suppression of TNF release and for treatment of autoimmune and inflammatory diseases)

RN 205806-93-5 HCAPLUS

CN Butanediamide, N1-hydroxy-2-[[2-(2-methoxyethoxy)ethoxy]methyl]-N4-[2-[[2-[[(4-methylphenyl)sulfonyl]amino]ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-3-(2-methylpropyl)-, [2R-[2R*,3R*,4(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205806-95-7 HCAPLUS

CN L-Alaninamide, N-[(2R)-2-[(1R)-2-(hydroxyamino)-1-[[2-(2-methoxyethoxy)ethoxy]methyl]-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205807-08-5 HCAPLUS

CN Butanediamide, N1-hydroxy-N4-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-[[2-(2-methoxyethoxy)ethoxy]methyl]-3-(2-methylpropyl)-, [2R-[2R*,3R*,4(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205807-28-9 HCAPLUS
CN Butanediamide, 2-[[2-(cyclohexyloxy)ethoxy]methyl]-N1-hydroxy-N4-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-3-(2-methylpropyl)-, [2R-[2R*,3R*,4(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 39 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:161082 HCAPLUS
DOCUMENT NUMBER: 128:205148
TITLE: Preparation of peptide sulfonamides as inhibitors of tumor necrosis factor
INVENTOR(S): Barlaam, Bernard Christophe
PATENT ASSIGNEE(S): Zeneca Limited, Fr.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807742	A1	19980226	WO 1997-GB2222	19970819

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9740217	A1	19980306	AU 1997-40217		19970819
ZA 9707580	A	19990217	ZA 1997-7580		19970822
PRIORITY APPLN. INFO.:			FR 1996-1815	A	19960823
			FR 1996-2031	A	19960925
			EP 1996-401815	A	19960823
			EP 1996-402031	A	19960925
			WO 1997-GB2222	W	19970819

OTHER SOURCE(S): MARPAT 128:205148

AB Peptide sulfonamides HONHCOCH(NHSO2R1)CHR2CONHCHR3CONR4R5 (R1 = aryl, heterocyclyl, heteroaryl; R2 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, aryl-, heteroaryl-, heterocyclyl- or cycloalkylalkyl; R3 = alkyl, alkenyl, aryl, alkyl, heteroarylalkyl or the side-chain of a naturally occurring amino acid; R4 = H, alkyl, cycloalkyl, cycloalkenyl, aryl-, heteroaryl- or heterocyclylalkyl; R5 = H, alkyl or R4R5N = heterocyclyl; any group or ring in R1-R5 is optionally substituted) or their pharmaceutically acceptable salts or in vivo hydrolyzable esters were prepared as inhibitors of the production of tumor necrosis factor and/or one or more matrix metalloproteinase enzymes. Thus, N2-[4-(hydroxyamino)-2R-isobutyl-3S-benzenesulfonylaminosuccinyl]-L-leucine-N1-methylamide was prepared via sequential benzenesulfonylation, deprotection, and hydroxylamination of intermediate N2-[2R-isobutyl-3S-amino-4-tert-butyloxysuccinyl]-L-leucine-N1-methylamide.

IT **204125-87-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide sulfonamides as inhibitors of tumor necrosis factor)

RN 204125-87-1 HCAPLUS

CN L-Valinamide, (3R)-N-hydroxy-3-(2-methylpropyl)-N2-(8-quinolinylsulfonyl)-L-α-asparaginyl-N-[2-(dimethylamino)ethyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 40 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:756963 HCAPLUS

DOCUMENT NUMBER: 127:359105

TITLE: Preparation of sulfur-containing aminoacyl hydroxamic acid derivatives as tumor necrosis factor and matrix

metalloproteinase inhibitors
INVENTOR(S): Bird, Thomas Geoffrey Colerick; Barlaam, Bernard Christophe; Lambert, Christine Marie Paul
PATENT ASSIGNEE(S): Zeneca Limited, Fr.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742168	A1	19971113	WO 1997-GB1164	19970429
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9726454	A1	19971126	AU 1997-26454	19970429
ZA 9703842	A	19971106	ZA 1997-3842	19970505

PRIORITY APPLN. INFO.: FR 1996-958 A 19960506
EP 1996-402032 A 19960925
FR 1996-2032 A 19960925
EP 1996-400958 A 19960506
WO 1997-GB1164 W 19970429

OTHER SOURCE(S): MARPAT 127:359105
GI



I



II



III

AB Title compds. I [R1 = aryl, aryl-C1-6 alkyl, heteroaryl, heteroaryl-C1-6 alkyl; R2 = H, C1-8 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heteroaryl, heterocyclyl, aryl-C1-6 alkyl, heteroaryl-C1-6 alkyl, heterocyclyl-C1-6 alkyl, C3-8 cycloalkyl-C1-6 alkyl; R3 = C1-6 alkyl, C2-6 alkenyl, aryl, C1-6 alkyl, heteroaryl-C1-6 alkyl, naturally occurring

Searched by P. Ruppel

amino acid side chain; R4 = H, C1-6 alkyl, C3-8 cycloalkyl, C4-8 cycloalkenyl, aryl-C1-6 alkyl, heteroaryl-C1-6 alkyl, heterocyclyl-C1-6 alkyl; R5 = H, C1-6 alkyl; NR4R5 = heterocyclic ring; wherein any group or ring in R1-R5 may be (un)substituted] or pharmaceutically acceptable salts or in vivo hydrolyzable esters thereof, are described as inhibitors of the production of tumor necrosis factor and/or one or more matrix metalloproteinase enzymes. Compns. containing I and their preparation are also described. Thus, deprotonation of 3.45 g (2R)-isobutyl-1,4-butanedioic acid 4-tert-Bu ester and reaction with 4.2 g Ph2S2 gave 2.3 g (2S,3S)-adduct II, along with 2.2 g of the corresponding (2S,3R)-adduct. Coupling of 2.75 g II with 1.41 g L-tert-leucine methylamide gave 3.0 g adduct III (R = OCMe3), which underwent deprotection with CF3CO2H and hydroxyamidation with hydroxylamine hydrochloride to give desired title compound III (R = NHOH).

IT **198421-34-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfur-containing aminoacyl hydroxamic acid derivs. as tumor necrosis factor and matrix metalloproteinase inhibitors)

RN 198421-34-0 HCAPLUS

CN Butanediamide, N1-[1-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2,2-dimethylpropyl]-N4-hydroxy-2-(2-methylpropyl)-3-[(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)thio]-, [2S-[1(R*),2R*,3R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 41 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:499085 HCAPLUS
DOCUMENT NUMBER: 127:180935
TITLE: Inhibition of skin photoaging by inhibitors of matrix metalloproteinase production
INVENTOR(S): Voorhees, John J.; Fisher, Gary J.
PATENT ASSIGNEE(S): University of Michigan, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725969	A1	19970724	WO 1997-US791	19970117

W: AU, BB, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KP, KR, LT, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5837224	A	19981117	US 1996-588771	19960119	
CA 2241981	AA	19970724	CA 1997-2241981	19970117	
CA 2241981	C	20020319			
AU 9718317	A1	19970811	AU 1997-18317	19970117	
AU 701132	B2	19990121			
EP 883398	A1	19981216	EP 1997-903847	19970117	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
CN 1211178	A	19990317	CN 1997-191735	19970117	
CN 1086937	B	20020703			
BR 9707018	A	19990720	BR 1997-7018	19970117	
JP 2000503660	T2	20000328	JP 1997-526224	19970117	
CZ 291530	B6	20030312	CZ 1998-2258	19970117	
NO 9803019	A	19980819	NO 1998-3019	19980629	
LT 4515	B	19990625	LT 1998-91	19980709	
HK 1018885	A1	20021122	HK 1999-103976	19990914	

PRIORITY APPLN. INFO.: US 1996-588771 A 19960119
WO 1997-US791 W 19970117

AB Photoaging of undamaged skin due to UVB irradiation exposure is inhibited by administering an agent that inhibits at least one of (1) the activity of UVB irradiation inducible MMPs in the skin, (2) one or both of the transcription factors AP-1 and NF- B or (3) at least one of the GTP binding proteins or kinases involved in the activation and/or production of jun of fos proteins that comprise AP-1; and topically administering said inhibitor to the skin prior to such exposure. A solution of 0.1% all-trans retinoic acid (I) in 70% ethanol and 30% propylene glycol was applied to the skin of volunteers for 48 h, the skin sites were then irradiated with 2 minimal erythema dose (1 MED = 30-50 mJ/cm2). I reduced UVB-induced MMP-1 and MMP-9 mRNAs, proteins and activity by 50-80%.

IT **142880-36-2**, Galardin
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibition of skin photoaging by inhibitors of matrix metalloproteinase production)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 42 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:70379 HCAPLUS
DOCUMENT NUMBER: 126:171901

TITLE: Preparation of peptide derivatives as inhibitors of TNF-α secretion

INVENTOR(S): Black, Roy A.; Fitzner, Jeffrey N.; Sleath, Paul R.

PATENT ASSIGNEE(S): Immunex Corporation, USA

SOURCE: U.S., 28 pp., Cont.-in-part of U.S. Ser. No. 110, 601, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: **Patent**

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5594106	A	19970114	US 1994-292547	19940818
US 5629285	A	19970513	US 1996-651363	19960522

PRIORITY APPLN. INFO.: US 1993-110601 19930823
US 1994-292547 19940818

OTHER SOURCE(S): MARPAT 126:171901

GI



II

AB Peptide derivs. having active groups capable of inhibiting TNF-α converting enzyme (TACE), such as hydroxamates, thiols, phosphoryls and carboxyls X(CHR1)mCHR2CONHCHR3CO(A)nNHBNH2 [I; X = hydroxamic acid, thiol, phosphoryl, carboxyl; m = 0-2; R1, R2, R3 = independently H, alkylene(cycloalkyl), OR4, NR4R5, halo, (un)substituted C1-8 alkyl, C1-8 alkylenearyl, aryl, (un)protected natural amino acid side chain, R6R7; R4, R5 = independently H, (un)substituted C1-8 alkyl; R6 = (un)substituted C1-8 alkyl; R7 = OR4, NR4R5, halo; n = 0-2; each A = same or different (un)protected α-amino acid radical; B = (un)substituted C2-8 alkylene], pharmaceutically acceptable salts thereof, and methods for preparing them are disclosed. I are useful in inhibiting TACE responsible for cleavage of TNF-α precursor to provide biol. active TNF-α. Thus, coupling of MeO2CCH2CH(CH2CHMe2)CO2Su (Su = succinimido; preparation given) with dipeptide H-Nal-Ala-NHCH2CH2NHZ (Nal = 2-naphthyl-L-alanine; Z = CO2CH2Ph; prepn given), condensation with hydroxylamine and catalytic hydrogenolysis, gave hydroxamate inhibitor II. II shows selective in vitro and in vivo inhibition of TNF-α secretion.

IT **143457-42-5P 163847-77-6P 163958-63-2P**
163958-73-4P 163958-74-5P 171235-71-5P
187034-27-1P 187034-28-2P 187034-29-3P
187034-30-6P 187034-31-7P 187034-32-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide derivs. as inhibitors of TNF-α converting enzyme inhibitors)

RN 143457-42-5 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-77-6 HCAPLUS
CN L-Alaninamide, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-63-2 HCAPLUS
CN L-Alaninamide, N-[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-73-4 HCAPLUS
CN L-Alaninamide, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-74-5 HCAPLUS
CN L-Alaninamide, N-[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171235-71-5 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-27-1 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-arginyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-28-2 HCAPLUS
CN L-Alaninamide, N2-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-lysyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-29-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-30-6 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-31-7 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methyl-L-valyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-32-8 HCAPLUS
CN L-Alaninamide, N2-[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-lysyl-N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **187034-36-2P 187034-41-9P 187034-44-2P**
187034-47-5P 187034-49-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptide derivs. as inhibitors of TNF-α converting enzyme inhibitors)

RN 187034-36-2 HCAPLUS

CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-(9CI). (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-41-9 HCAPLUS

CN L-Alaninamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-ornithyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-44-2 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-47-5 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-N6-(phenylmethyl)-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187034-49-7 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 43 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:51546 HCAPLUS
DOCUMENT NUMBER: 126:89699
TITLE: Process for the preparation of activated glycomimetic C-glycosides as selectin inhibitors
INVENTOR(S): Anderson, Mark Brian; Musser, John H.
PATENT ASSIGNEE(S): Glycomed Incorporated, USA
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9636627	A1	19961121	WO 1996-US6522	19960520
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
CA 2221589	AA	19961121	CA 1996-2221589	19960520
AU 9658552	A1	19961129	AU 1996-58552	19960520
EP 828729	A1	19980318	EP 1996-920158	19960520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11507020	T2	19990622	JP 1996-534893	19960520

PRIORITY APPLN. INFO.: US 1995-446185 19950519
WO 1996-US6522 19960520

OTHER SOURCE(S): MARPAT 126:89699
GI



I

AB Combinatorial library and process for the preparation of title C-glycosides I (A = O, S, imino; Z = alkyl, alkenyl, arylalkyl; U = alkoxymethyl, carbonyl, R = H, Me, alkyl, sulfonyl, sugar; n = 1-3) as selectin inhibitors, are reported. Thus, 2-chloromethyl-3-(tetra-O-acetyl-α-L-mannopyranoside)-1-propene was prepared as selectin inhibitor (no data).

IT **185334-73-0P 185334-74-1P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of activated glycomimetic C-glycosides as selectin inhibitors)

RN 185334-73-0 HCAPLUS

CN L-glycero-D-galacto-Nonitol, 2,6-anhydro-1,7,8,9-tetradeoxy-9-[hydroxy[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]amino]-8-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185334-74-1 HCAPLUS

CN L-glycero-D-galacto-Nonitol, 2,6-anhydro-1,7,8,9-tetradeoxy-9-[[(2S)-2-[[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]-8-methylene- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 44 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:452771 HCAPLUS
DOCUMENT NUMBER: 125:105111
TITLE: Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors
INVENTOR(S): Gijbels, Koenraad; Steinman, Lawrence
PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior University, USA

SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5532265	A	19960702	US 1994-348262	19941130

PRIORITY APPLN. INFO.: US 1994-348262 19941130

AB A synthetic inhibitor of matrix metalloproteases, the tripeptide hydroxamate GM 6001, is administered to a patient suffering from an inflammatory disease of the central nervous system. The treatment diminishes the adverse effects of an inflammatory central nervous system disease associated with elevated matrix metalloprotease activity in the central nervous system. The effect is mediated primarily through restoration of the blood-CNS barrier.

IT **142880-36-2**, GM 6001
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix metalloprotease inhibitor GM 6001 for treatment of adverse effects of central nervous system inflammatory disease associated with elevated matrix metalloprotease activity)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 45 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:332351 HCAPLUS
DOCUMENT NUMBER: 125:11473
TITLE: Preparation of N-(N-hydroxy-2-isobutyl-3-methylsuccinamyl)amino acid derivatives as collagenase inhibitors
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 08053403	A2	19960227	JP 1995-151923	19950619
PRIORITY APPLN. INFO.:			GB 1994-12350	19940620
OTHER SOURCE(S):	MARPAT 125:11473			

GI



I



II

AB The title hydroxamic acid (I; R1 = H, OH-protective group; R2 = H, lower alkyl, NH2-protective group; R3 = H, 2-thienylthio; R4 = 2-pyridyl or its N-oxide, 4-pyridyl, Ph, 4-methoxyphenyl; R5 = HO, lower alkoxy, substituted NH2; provided that when R1 = R2 = H, R4 = 2-pyridyl or its N-oxide) or pharmaceutically acceptable salts, which are useful for the treatment or prevention of collagenase-mediated diseases such as destruction of joints in rheumatoid arthritis, pericementosis, ulcers of the cornea, tumor metastasis, deforming arthritis, osteoporosis, psoriasis, chronically active hepatitis, autoimmune keratitis, etc., are prepared Thus, N-succinyl-L-(2-pyridyl)alanine-N-methylamide derivative (R = HO) was condensed with hydroxylamine hydrochloride using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N-hydroxybenzotriazole, and (Me2CH)2NEt in DMF at 0° for 1 h to give the title compound (II; R = HONH). This compound in vitro showed IC50 of 1.5 nM against human collagenase.

IT **177162-56-0P 177162-59-3P 177162-62-8P**
177162-67-3P 177162-72-0P 177162-73-1P
177162-74-2P 177162-75-3P 177162-76-4P
177162-77-5P 177162-78-6P 177162-79-7P
177162-80-0P 177162-81-1P 177162-82-2P
177162-83-3P 177162-84-4P 177162-90-2P
177162-91-3P 177162-92-4P 177163-05-2P
177163-07-4P 177163-18-7P 177163-19-8P
177163-21-2P 177163-22-3P 177163-30-3P
177163-50-7P 177163-51-8P 177163-52-9P
177163-53-0P 177163-61-0P 177163-63-2P
177163-74-5P 177163-75-6P 177163-77-8P
177163-78-9P 177163-86-9P 177164-06-6P

177164-07-7P 177164-08-8P 177164-09-9P
177164-16-8P 177164-17-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(N-hydroxy-2-isobutyl-3-methyl-succinamyl)amino acid derivs. as collagenase inhibitors)

RN 177162-56-0 HCAPLUS
CN Butanediamide, N4-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-59-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-62-8 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-(2,2-dimethyl-1-oxopropoxy)-4-methyl-5-(2-methylpropyl)-3,6,9,14-tetraoxo-8-(2-pyridinylmethyl)-2,7,10,13-tetraazapentadec-1-yl ester, [4S-(4R*,5S*,8R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-67-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-(2,2-dimethyl-1-oxopropoxy)-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-72-0 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-73-1 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-[[2-[(4-

morpholinylcarbonyl)amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-74-2 HCAPLUS
CN Butanediamide, 2-methyl-N4-[2-[[2-[methyl(4-morpholinylcarbonyl)amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-75-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-76-4 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-oxo-1-(2-pyridinylmethyl)-2-[[2-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]ethyl]amino]ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-77-5 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-78-6 HCAPLUS
CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-[[2-[(4-

morpholinylcarbonyl)amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-79-7 HCAPLUS
CN Butanediamide, N1-hydroxy-2-methyl-N4-[2-[[2-[methyl(4-morpholinylcarbonyl)amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-80-0 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(hexahydro-1H-azepin-1-yl)carbonyl]amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-81-1 HCAPLUS
CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-oxo-1-(2-pyridinylmethyl)-2-[[2-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]ethyl]amino]ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-82-2 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-(2,2-dimethyl-1-oxopropoxy)-4,15-dimethyl-5-(2-methylpropyl)-3,6,9,14-tetraoxo-8-(2-pyridinylmethyl)-2,7,10,13,15-pentaazahexadec-1-yl ester, [4S-(4R*,5S*,8R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Searched by P. Ruppel

RN 177162-83-3 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-(2,2-dimethyl-1-oxopropoxy)-4-methyl-5-(2-methylpropyl)-14-(4-morpholinyl)-3,6,9,14-tetraoxo-8-(2-pyridinylmethyl)-2,7,10,13-tetraazatetradec-1-yl ester, [4S-(4R*,5S*,8R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-84-4 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]amino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(1-oxopropoxy)-N1-[(1-oxopropoxy)methyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-90-2 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]amino]ethyl]amino]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-91-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]amino]ethyl]amino]-1-[(4-methoxyphenyl)methyl]-2-oxoethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177162-92-4 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-(2,2-dimethyl-1-oxopropoxy)-8-[(4-methoxyphenyl)methyl]-4,15-dimethyl-5-(2-methylpropyl)-3,6,9,14-tetraoxo-2,7,10,13,15-pentaazahexadec-1-yl ester, [4S-(4R*,5S*,8R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-05-2 HCAPLUS
CN 2-Oxa-3,8,11,14-tetraazapentadecan-15-oic acid, 5-methyl-6-(2-methylpropyl)-4,7,10-trioxo-1-phenyl-9-(2-pyridinylmethyl)-, 2-methylpropyl ester, [5S-(5R*,6S*,9R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-07-4 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(diethylamino)carbonyl]ethylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-18-7 HCAPLUS
CN 2-Oxa-3,8,11,14-tetraazapentadecan-15-oic acid, 5-methyl-6-(2-methylpropyl)-4,7,10-trioxo-1-phenyl-9-(2-pyridinylmethyl)-, phenyl ester, [5S-(5R*,6S*,9R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-19-8 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]methylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-21-2 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(diethylamino)carbonyl]methylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-22-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]ethylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-

(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-30-3 HCAPLUS
CN Butanediamide, N4-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(4-pyridinylmethyl)ethyl]-2-methyl-3-(2-methylpropyl)-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-50-7 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(2-pyridinylcarbonyl)amino]ethyl]amino]-1-(2-pyridinylmethyl)ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-51-8 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(3-pyridinylcarbonyl)amino]ethyl]amino]-1-(2-pyridinylmethyl)ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-52-9 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(3-pyridinylcarbonyl)amino]ethyl]amino]-1-(4-pyridinylmethyl)ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-53-0 HCAPLUS
CN Butanediamide, 2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(2-pyridinylcarbonyl)amino]ethyl]amino]-1-(4-pyridinylmethyl)ethyl]-N1-(phenylmethoxy)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-61-0 HCAPLUS
CN Carbamic acid, [2-[[2-[[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-1-oxo-3-(2-pyridinyl)propyl]amino]ethyl]-, 2-methylpropyl ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-63-2 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(diethylamino)carbonyl]ethylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-74-5 HCAPLUS
CN Carbamic acid, [2-[[2-[[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-1-oxo-3-(2-pyridinyl)propyl]amino]ethyl]-, phenyl ester, [2R-[1(S*),2R*(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-75-6 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]methylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-77-8 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(diethylamino)carbonyl]methylamino]ethyl]amino]-

2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-78-9 HCAPLUS
CN Butanediamide, N4-[2-[[2-[[(dimethylamino)carbonyl]ethylamino]ethyl]amino]-2-oxo-1-(2-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177163-86-9 HCAPLUS
CN Butanediamide, N4-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(4-pyridinylmethyl)ethyl]-N1-hydroxy-2-methyl-3-(2-methylpropyl)-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-06-6 HCAPLUS
CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(2-pyridinylcarbonyl)amino]ethyl]amino]-1-(2-pyridinylmethyl)ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-07-7 HCAPLUS
CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(3-pyridinylcarbonyl)amino]ethyl]amino]-1-(2-pyridinylmethyl)ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-08-8 HCAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(3-pyridinylcarbonyl)amino]ethyl]amino]-1-(4-pyridinylmethyl)ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-09-9 HCAPLUS

CN Butanediamide, N1-hydroxy-2-methyl-3-(2-methylpropyl)-N4-[2-oxo-2-[[2-[(2-pyridinylcarbonyl)amino]ethyl]amino]-1-(4-pyridinylmethyl)ethyl]-, [2S-[2R*,3S*,4(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-16-8 HCAPLUS

CN 15-Oxa-2,5,8,13-tetraazaoctadecanoic acid, 13-(2,2-dimethyl-1-oxopropoxy)-11,17,17-trimethyl-10-(2-methylpropyl)-6,9,12,16-tetraoxo-7-(2-pyridinylmethyl)-, 2-methylpropyl ester, [7S-(7R*,10S*,11R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177164-17-9 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-(2,2-dimethyl-1-oxopropoxy)-13,15-diethyl-4-methyl-5-(2-methylpropyl)-3,6,9,14-tetraoxo-8-(2-pyridinylmethyl)-2,7,10,13,15-pentaazaheptadec-1-yl ester, [4S-(4R*,5S*,8R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 46 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:978677 HCAPLUS
DOCUMENT NUMBER: 124:30411
TITLE: Tryptophan derivatives as synthetic matrix metalloprotease inhibitors and uses thereof
INVENTOR(S): Levy, Daniel E.; Grobelny, Damian; Tang, Peng Cho; Holme, Kevin R.; Galardy, Richard E.; Schultz, Gregory S.; Nematalla, Assad; Musser, John H.
PATENT ASSIGNEE(S): Glycomed Incorp., USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519965	A1	19950727	WO 1995-US783	19950120
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5892112	A	19990406	US 1994-184727	19940121
AU 9516049	A1	19950808	AU 1995-16049	19950120
EP 690841	A1	19960110	EP 1995-908086	19950120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09501183	T2	19970204	JP 1995-519668	19950120

PRIORITY APPLN. INFO.:

US 1994-184727	A	19940121
US 1990-616021	A1	19901120
US 1990-615798	A2	19901121
US 1991-747751	A1	19910820
US 1991-747752	A2	19910820
US 1992-817039	A2	19920107
US 1992-881630	A1	19920512
US 1993-44324	A2	19930407
WO 1995-US783	W	19950120

OTHER SOURCE(S): CASREACT 124:30411; MARPAT 124:30411

AB Synthetic mammalian matrix metalloprotease inhibitors are disclosed, that are useful for treating or preventing diseases including skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock. The compds. include those of general formula R7ON(R6)CO(CHR1)nCH(R2)CON(R3)CH(R4)COX [where R1 = H, alkyl; R2 = H, alkyl, NHZ; Z = alkyl, alkanoyl, alkoxycarbonyl; or R1R2 = (CH2)3-5; R3 = H, alkyl; R4 = fused or conjugated (un)substituted bicycloarylmethylene; n = 0-2; X = OH, alkoxy, amino, alkylamino, amino acid or amide; R6 = H, alkyl; R7 = H, alkyl, acyl; amide group CONR3 may be replaced by selected isosteric groups]. For example, benzyl 4-methyl-2-oxopentanoate underwent Wittig reaction with Ph3P:CHCO2Me (100%), hydrogenation of the formed unsatd. diester (86%), peptide coupling of the obtained monoacid with H-Trp-NHMe.HCl and separation of diastereomers (83%), and reaction with NH2OH (56% and 72%), to give title compds. D,L- and L,L-HONHCOCH2CH(Bu-iso)CO-Trp-NHMe (I). In the phorbol ester-induced epidermal hyperplasia mouse model, D,L-I reduced ear thickness from 229% of control to only 140% of control. Over 40 synthetic examples are given, plus enzyme assays, and addnl. biol. tests showing activity against angiogenesis, chronic dermal wounds, peritonitis, metastasis, hypovolemic shock, and restenosis.

IT **171347-98-1P 171348-01-9P 171348-02-0P**
171348-03-1P 171348-04-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of tryptophan derivs. as matrix metalloprotease inhibitors)

RN 171347-98-1 HCAPLUS

CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-01-9 HCAPLUS
CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-N4-(phenylmethyl)-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-02-0 HCAPLUS
CN Butanediamide, N4-[(4-fluorophenyl)methoxy]-N4-[(4-fluorophenyl)methyl]-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171348-03-1 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl](phenylmethoxy)amino]methyl ester (9CI) (CA INDEX NAME)

Searched by P. Ruppel

Absolute stereochemistry.



RN 171348-04-2 HCAPLUS
CN Glycine, N-[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]-N-(phenylmethoxy)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142880-36-2P 142880-37-3P 142880-40-8P**
142880-46-4P 142880-59-9P 142880-60-2P
142880-62-4P 142902-71-4P 144007-87-4P
159686-32-5P 159686-33-6P 159686-34-7P
162550-05-2P 171347-79-8P 171347-80-1P
171347-81-2P 171347-82-3P 171347-83-4P
171347-84-5P 171347-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tryptophan derivs. as matrix metalloprotease inhibitors)
RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-40-8 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-46-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-59-9 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

RN 142880-60-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142902-71-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-87-4 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-32-5 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-33-6 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-34-7 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 162550-05-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-79-8 HCAPLUS
CN Butanediamide, N1-hydroxy-N4-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-3-(2-methylpropyl)-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 171347-80-1 HCAPLUS
CN Butanediamide, N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-81-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-82-3 HCAPLUS
CN Butanediamide, N4-[(4-fluorophenyl)methyl]-N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-83-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N4-(methoxymethyl)-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-84-5 HCAPLUS
CN Butanediamide, N4-(3,3-dimethyl-2-oxobutyl)-N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171347-85-6 HCAPLUS
CN Glycine, N-hydroxy-N-[(3R)-3-[[[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]amino]carbonyl]-5-methyl-1-oxohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 47 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:934125 HCAPLUS
DOCUMENT NUMBER: 123:330041
TITLE: Medical use of matrix metalloproteinase (MMP) inhibitors for inhibiting tissue contraction
INVENTOR(S): Khaw, Peng Tee; Schultz, Gregory Scott
PATENT ASSIGNEE(S): Institute of Ophthalmology, UK; University of Florida
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524921	A1	19950921	WO 1995-GB576	19950316

W: AM, AT, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, CZ, DE, DE, DK, DK, EE, ES, FI, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9518985		A1	19951003	AU 1995-18985	19950316
EP 750512		A1	19970102	EP 1995-911409	19950316
	R: CH, DE, FR, GB, IT, NL				
US 6093398		A	20000725	US 1996-716155	19961119
US 6379667		B1	20020430	US 1999-368307	19990803
US 2002164319		A1	20021107	US 2002-135934	20020429

PRIORITY APPLN. INFO.:

GB 1994-5076	A	19940316
WO 1995-GB576	W	19950316
US 1996-716155	A3	19961119
US 1999-368307	A3	19990803

AB An MMP inhibitor, especially a collagenase inhibitor, is useful in the manufacture of a medicament for the treatment of a natural or artificial tissue containing extracellular matrix components to inhibit contraction of the tissue, e.g. to prevent scar contracture in the skin or eye, by inhibiting invasion of the tissue by fibroblasts. This effect was demonstrated in collagen gels seeded with ocular fibroblasts and treated with the MMP inhibitor Galardin or with antibodies to MMP 1, 2, or 3.

IT **142880-36-2**, Galardin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 48 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1995:750507 HCAPLUS
DOCUMENT NUMBER:	123:144644
TITLE:	Preparation of hydroxamic acid-containing amino acid and peptide derivatives as metalloproteinase and tumor necrosis factor release inhibitors
INVENTOR(S):	Crimmin, Michael John; Ayscough, Andrew Paul; Beckett, Raymond Paul
PATENT ASSIGNEE(S):	British Bio-Technology Ltd., UK
SOURCE:	PCT Int. Appl., 51 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9424140	A1	19941027	WO 1994-GB808	19940418
W: AU, CA, CN, CZ, DE, FI, GB, HU, JP, KR, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9465102	A1	19941108	AU 1994-65102	19940418
EP 694036	A1	19960131	EP 1994-912635	19940418
EP 694036	B1	19970305		
R: BE, DE, ES, FR, GB, IT, NL, SE				
US 5696082	A	19971209	US 1996-530374	19960528
PRIORITY APPLN. INFO.:			GB 1993-7956	19930417
			WO 1994-GB808	19940418

OTHER SOURCE(S): MARPAT 123:144644

GI



I





AB R1CHXCHR2CONHCHR3CONR4R5 [R1 = H alkyl, Ph, heterocyclyl, etc.; R2 = (phenyl)alkyl, heteroarylalkyl, etc.; R3 = ZCOR6, ZC6H4Z1R6, amino acid side chain, etc.; R4 = (CHR7CONH)mCOR6, H, alkyl, etc.; R5 = H, alkyl; R6 = pyranosylamino group Q1; R7 = H, amino acid side chain; X = CONHOH, CO2H; Z = alkylene; Z1 = CO,CH2CH2CO, OCH2CO, NHCH2CO] were prepared Thus, succinyltyrosine deriv, I (R = OH, X = CO2CMe2) was amidated by pyranosylamine Q2H and the product converted in 3 addnl. steps to I (R = Q2, X = NONHOH) which had IC50 of 20 and 600nM against collagenase and stromelysin, resp., in vitro.

IT **166811-02-5P 166811-03-6P 166811-05-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acid-containing amino acid and peptide derivs. as metalloproteinase and tumor necrosis factor release inhibitors)

RN 166811-02-5 HCAPLUS

CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, (R)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166811-03-6 HCAPLUS
CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanylglycyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166811-05-8 HCAPLUS
CN Glycinamide, N-[2-[1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **166811-10-5P 166811-11-6P 166811-17-2P**
166811-24-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxamic acid-containing amino acid and peptide derivs. as metalloproteinase and tumor necrosis factor release inhibitors)

RN 166811-10-5 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl-N-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166811-11-6 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166811-17-2 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanylglycyl-N-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 166811-24-1 HCAPLUS
CN Glycinamide, N-[2-[1-hydroxy-2-oxo-2-[(phenylmethoxy)amino]ethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 49 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:615213 HCAPLUS
DOCUMENT NUMBER: 123:33659
TITLE: Preparation of peptides as inhibitors of tumor necrosis factor-alpha (TNF-alpha) secretion
INVENTOR(S): Black, Roy A.; Fitzner, Jeffrey N.; Sleath, Paul R.
PATENT ASSIGNEE(S): Immunex Corp., USA
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9506031	A1	19950302	WO 1994-US9343	19940819
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9475694	A1	19950321	AU 1994-75694	19940819
AU 687436	B2	19980226		
EP 715619	A1	19960612	EP 1994-925940	19940819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09503201	T2	19970331	JP 1994-507668	19940819
FI 9600803	A	19960422	FI 1996-803	19960222
NO 9600723	A	19960223	NO 1996-723	19960223
AU 9850302	A1	19980305	AU 1998-50302	19980106

PRIORITY APPLN. INFO.: US 1993-110601 19930823
US 1994-183019 19940118
WO 1994-US9343 19940819

OTHER SOURCE(S): MARPAT 123:33659
GI



I

AB X[CHR1]mCHR2CONHCHR3CO[A]nNH-B-NH2 [X = hydroxamic acid, thiol, phosphoryl, CO2H; m = 0,1,2; R1 - R3 = H, alkylene-cycloalkyl, OR4, SR4, NR4R5, halo, (un)substituted C1-8 alkyl, C1-8 alkylene-aryl, aryl, (un)protected side chain of a naturally occurring α-amino acid, or group R6R7; wherein R6 = (un)substituted C1-8 alkyl and R7 = OR4, SR4, NR4R5, or halo; wherein R4, R5 = H, (un)substituted C1-8 alkyl; n = 0,1,2; provided that when n = 1, A = (un)protected amino acid radical; when n = 2, A = same or different (un)protected amino acid radical; B = (un)substituted C2-8 alkylene] and pharmaceutically acceptable salts thereof, which are inhibitors of metalloproteases and, in particular, TNF-α converting enzyme (TACE), are prepared These peptides have active groups capable of inhibiting TACE responsible for cleavage of TNF-α precursor to provide biol. active TNF-α and are useful for treating a mammal having a disease characterized by an overprodn. or an unregulated production of TNF-α. Thus, DL-2-isobutyl-3-(methoxycarbonyl)propionic acid N-hydroxysuccinimide ester (preparation given) was added to a solution of L-3-(2-naphthyl)alanyl-L-alanine 2-(benzyloxycarbonylamino)ethylamide and Et3N in DMF and stirred at room temperature for 18 h to give a dipeptide derivative (I; R = MeO, A1 = CO2CH2Ph) (89% yield), which was condensed with HONH2 in MeOH containing KOH in an ice-bath to give 86% I (R = HONH, A1 = CO2CH2Ph). The latter compound was hydrogenolyzed over 10% Pd-C in glacial AcOH to give a title peptide I.AcOH (R = HONH, A1 = H). The latter peptide at 200 μM in vitro inhibited TNF-α release from T-cells by 72 and 63% at 24 and 48 h, resp., while there was no inhibitory effect on the release of TNF-β or interferon-γ.

IT **163847-98-1P 163848-00-8P 163848-03-1P**
163848-05-3P 163848-20-2P 163958-73-4P
163958-74-5P 163958-76-7P 163958-78-9P
163958-80-3P 163958-82-5P 163958-85-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of peptides as inhibitors of TNF-α converting enzyme and TNF-α secretion)

RN 163847-98-1 HCAPLUS

CN L-Alaninamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-ornithyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 163848-00-8 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163848-03-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-O-(phenylmethyl)-L-tyrosyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163848-05-3 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-O-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163848-20-2 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-73-4 HCAPLUS
CN L-Alaninamide, N-[(2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-74-5 HCAPLUS
CN L-Alaninamide, N-[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Searched by P. Ruppel



RN 163958-76-7 HCAPLUS
CN L-Alaninamide, N5-[bis[[(phenylmethoxy)carbonyl]amino]methylene]-N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-ornithyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 163958-78-9 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-80-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-O-

(phenylmethyl)-L-tyrosyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-82-5 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-O-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-85-8 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-[2-[[(phenylmethoxy)carbonyl]amino]ethyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **163847-78-7P 163847-82-3P 163847-83-4P**
163847-84-5P 163847-87-8P 163847-88-9P
163958-64-3P 163958-65-4P 163958-66-5P

163958-67-6P 163958-68-7P 163958-69-8P
163958-70-1P 163958-71-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides as inhibitors of TNF-α converting enzyme and TNF-α secretion)

RN 163847-78-7 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-(2-aminoethyl)-, (R)-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 163847-77-6
CMF C26 H37 N5 O5

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 163847-82-3 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-arginyl-N-(2-aminoethyl)-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 163847-83-4 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-lysyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-84-5 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tyrosyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163847-87-8 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-, (R)- (9CI) (CA INDEX NAME)

Searched by P. Ruppel

Absolute stereochemistry.



RN 163847-88-9 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-4-methyl-L-leucyl-N-(2-aminoethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-64-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-(2-aminoethyl)-, (S)-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 163958-63-2
CMF C26 H37 N5 O5

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 163958-65-4 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-arginyl-N-(2-aminoethyl)-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 163958-66-5 HCAPLUS
CN L-Alaninamide, N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-lysyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-67-6 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tyrosyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-68-7 HCAPLUS
CN L-Serinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-69-8 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-70-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 163958-71-2 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-4-methyl-L-leucyl-N-(2-aminoethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 50 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:248590 HCAPLUS
DOCUMENT NUMBER: 122:23869
TITLE: Preparation of synthetic matrix metalloprotease inhibitors as pharmaceuticals.
INVENTOR(S): Galardy, Richard Edward; Grobelny, Damian; Schultz, Gregory Scott
PATENT ASSIGNEE(S): Glycomed Incorp, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422309	A1	19941013	WO 1994-US3600	19940401
W: AU, CA, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2160139	AA	19941013	CA 1994-2160139	19940401
AU 9465542	A1	19941024	AU 1994-65542	19940401
EP 692931	A1	19960124	EP 1994-913345	19940401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08511509	T2	19961203	JP 1994-522412	19940401
AU 9883118	A1	19990128	AU 1998-83118	19980904

PRIORITY APPLN. INFO.: US 1993-44324 A 19930407
AU 1994-65542 A3 19940401

Searched by P. Ruppel

WO 1994-US3600 W 19940401

OTHER SOURCE(S): MARPAT 122:23869

AB Skin disorders, keratoconus, restenosis, wounds, and diseases that involve uncontrolled angiogenesis, are treated with synthetic mammalian matrix metalloprotease inhibitors. The inhibitors are R7ONR6CO(CHR1)nCHR2CONR3CHR4COX or R7ONR6CO(CHR1)mCR1:CR2CONR3CHR4COX [R1,R2,R3=H, alkyl;R1R2=(CH2)p;R4=fused or conjugated bicycloaryl methylene;X=OR5,NHR5;R5=H, alkyl, amino acid residue, etc.;R6=H, alkyl;R7=R6,acyl;m=0,1;n=0,1,2;p=3,4,5;the CONR3-amide bond is optionally replaced by CHNR3,CH2CHR3, etc.]. N-[D,L-2-isobutyl-3-(N'-hydroxycarbonylamido)propanoyl]tryptophan methylamide (preparation given) inhibited angiogenesis in the rat eye with induced Walker 256 carcinoma.

IT **142880-36-2P 142880-37-3P 142880-40-8P**
142880-46-4P 142880-60-2P 142880-62-4P
142902-71-4P 144007-87-4P 159686-32-5P
159686-33-6P 159686-34-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of synthetic matrix metalloprotease inhibitors as pharmaceuticals)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-40-8 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-

oxoethyl]-N1-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-46-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-60-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142902-71-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-87-4 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-32-5 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-33-6 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 159686-34-7 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



L20 ANSWER 51 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:19442 HCAPLUS
DOCUMENT NUMBER: 122:230797
TITLE: Inhibition of tumor necrosis factor (TNF) production
INVENTOR(S): Crimmin, Michael John; Galloway, William Alan; Gearing, Andrew John Hubert
PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 9410990	A1	19940526	WO 1993-GB2331	19931112
W: AU, CA, DE, ES, FI, GB, JP, KR, NO, NZ, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9454301	A1	19940608	AU 1994-54301	19931112
EP 667770	A1	19950823	EP 1993-924754	19931112
EP 667770	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08505605	T2	19960618	JP 1993-511862	19931112
AT 150300	E	19970415	AT 1993-924754	19931112
ES 2101358	T3	19970701	ES 1993-924754	19931112
US 5691382	A	19971125	US 1995-436190	19950512
PRIORITY APPLN. INFO.:			GB 1992-23904	19921113
			WO 1993-GB2331	19931112

AB Certain hydroxamic acid derivs., previously known as inhibitors of matrix metalloproteinases (e.g. collagenase) are capable of inhibiting the production of TNF by cells, and thus are useful in the management of diseases or conditions mediated by overprodn. of, or over-responsiveness to, TNF. The compds. in question are known in the art from the following patent publications: US 4599361, EP-A-0236872, EP-A-0274453, WO 90/05716, WO 90/05719,WO 91/02716, EP-A-0489577, EP-A-0489579, EP-A-0497192, WO 92/13831, WO 92/22523,WO 93/09090, and WO 93/09097. They have general formula CH(R1)(CONHOH)CH(R2)C(O)NHCH(R3)C(O)N(R4)(R5) or CH(R1)[N(OH)(CO)H]CH(R2)C(O)NHCH(R3)C(O)N(R4)(R5), in which substituents R1-R5 may vary widely according to the disclosures of those patent publications. Prevention of e.g. TNF release from phorbol myristate acetate-stimulated human monocytic cell line U937 by compds. of the invention is described.

IT **155865-40-0**
RL: BIOL (Biological study)
(TNF production inhibition by)

RN 155865-40-0 HCAPLUS

CN Butanediamide, N1-[2-[(2-aminoethyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 52 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1994:426909 HCAPLUS
DOCUMENT NUMBER:	121:26909
TITLE:	Vasoactive peptide inhibition
INVENTOR(S):	Crimmin, Michael John; Bone, Elisabeth Ann; Wood, Lars Michael
PATENT ASSIGNEE(S):	British Bio-Technology Ltd., UK
SOURCE:	PCT Int. Appl., 15 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407527	A2	19940414	WO 1993-GB2044	19931001
WO 9407527	A3	19940721		
W: AU, CA, FI, GB, JP, KR, NO, NZ, PT, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9348316	A1	19940426	AU 1993-48316	19931001
PRIORITY APPLN. INFO.:			GB 1992-20845 A	19921003
			WO 1993-GB2044 W	19931001

AB Certain known hydroxamic acid derivs. and their salts are useful as inhibitors of the conversion of big endothelin (I) to endothelin by a putative endothelin converting enzyme, and are useful in the management of diseases mediated by overprodn. of, over-responsiveness to, endothelin in mammals, e.g. hypertension. Thus, i.v. administration of 1mg [4-(N-hydroxyamino)-2R-isobutylsuccinyl]-L-phenylalanine/kg in rats 5 min before i.v. administration of I inhibited its activity by 62%.

IT **155832-42-1 155865-40-0**
RL: BIOL (Biological study)
(as inhibitor of big endothelin conversion to endothelin)

RN 155832-42-1 HCAPLUS
CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-N-methyl-, (R)- (9CI) (CA INDEX NAME)



RN 155865-40-0 HCAPLUS
CN Butanediamide, N1-[2-[(2-aminoethyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 53 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1994:245779 HCAPLUS
DOCUMENT NUMBER:	120:245779
TITLE:	Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
INVENTOR(S):	Galardy, Richard E.
PATENT ASSIGNEE(S):	Glycomed, Inc., USA
SOURCE:	PCT Int. Appl., 51 pp. CODEN: PIXXD2
DOCUMENT TYPE:	**Patent**

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9313741	A2	19930722	WO 1993-US54	19930104
WO 9313741	A3	19930819		
W: AU, CA, DK, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5268384	A	19931207	US 1992-817039	19920107
AU 9334332	A1	19930803	AU 1993-34332	19930104
JP 07503007	T2	19950330	JP 1993-512526	19930104
EP 663823	A1	19950726	EP 1993-902938	19930104
EP 663823	B1	20001122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 197667	E	20001215	AT 1993-902938	19930104

PRIORITY APPLN. INFO.:
US 1992-817039 A 19920107
US 1990-615798 A2 19901121
US 1991-747751 A2 19910820
US 1991-747752 A2 19910820
WO 1993-US54 A 19930104

OTHER SOURCE(S): MARPAT 120:245779

AB Peptides R7ONR6CO[CHR1]nCHR2CONR3CHR4COR5 [R1 = H, alkyl; R2 = alkyl; R1R2 = alkylene; R3 = H, alkyl; R4 = fused or conjugated (un)substituted bicycloarylmethyl; R5 = (un)substituted OH, NH2, amino acid residue; R6 = H, alkyl; R7 = H, alkyl, acyl; n = 0-2] were prepared as angiogenesis and metalloproteinase inhibitors. Thus, HONHCOCH2CH(CH2CHMe2)CO-L-Trp-NHMe (I) was prepared as a mixture of diastereomers from Me2CHCH2COCO2Na via reaction with Ph3P:CHCO2Me and H-Trp-NHMe.HCl. The isomers had matrix metalloproteinase-inhibiting Ki of 10 and 150 nM, resp.

IT **143985-51-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediate in preparation of metalloproteinase inhibiting hydroxylaminocarbonylalkanoyltryptophanamides)

RN 143985-51-7 HCAPLUS

CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, monopotassium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

IT **142880-36-2P 142880-37-3P 142880-38-4P**

142880-53-3P 142880-58-8P 142880-62-4P
143985-20-0P 143985-22-2P 144069-98-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and metalloproteinase inhibiting activity of)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-38-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-53-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-58-8 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-20-0 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-22-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144069-98-7 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)-, [2S-[N1[R*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **142880-53-3P 142880-75-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 142880-53-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-75-9 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 54 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:217274 HCAPLUS
DOCUMENT NUMBER: 120:217274
TITLE: Succinamide derivative matrix-metalloprotease inhibitors
INVENTOR(S): Singh, Jasbir; Morgan, Barry A.; Gainor, James A.; Gordon, Thomas D.; Wahl, Robert C.
PATENT ASSIGNEE(S): Sterling Winthrop, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5256657 A 19931026 US 1991-747887 19910819
PRIORITY APPLN. INFO.: US 1991-747887 19910819
OTHER SOURCE(S): MARPAT 120:217274
GI



I



II

AB The title compds., i.e. succinimide derivs. I (X = HO, HONH; R1 = alkyl; R2 = alkyl, amino acid side chain derivative etc.; R3 = alkyl; R4 = H, alkyl, etc.; m = 2-6; n = 0-1; p = 2-6) are claimed. I are agents for the treatment of diseases in which matrix metallo protease-promoted connective tissue remodeling is a causative factor (for example rheumatoid arthritis or cancer). I inhibited human fibroblast collagenase (collagenase inhibitors). An example compound, N-[[[[[(aminoethyl)thio]ethyl]amino]carbonyl](indolyl)ethyl]succinamide II was prepared in several steps. The in vitro IC50 of II toward human fibroblast collagenase was 8.8 μM.

IT **153465-42-0P 153465-46-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 153465-42-0 HCAPLUS

CN Butanediamide, N1-[2-[[2-[[2-(dimethylamino)ethyl]thio]ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153465-46-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-[[2-[[2-(4-morpholinyl)ethyl]thio]ethyl]amino]-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 55 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:473118 HCAPLUS
DOCUMENT NUMBER: 119:73118
TITLE: Peptide derivatives of collagenase inhibitor
INVENTOR(S): Gray, Robert D.; Spatola, Arno F.; Darlan, Krzysztof
PATENT ASSIGNEE(S): Research Corp. Technologies, Inc., USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222523	A2	19921223	WO 1992-US5118	19920612
WO 9222523	A3	19930121		
W: AU, CA, JP, KR				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
AU 9222282	A1	19930112	AU 1992-22282	19920612
US 5387610	A	19950207	US 1992-981149	19921124
US 5616605	A	19970401	US 1994-287320	19940808

PRIORITY APPLN. INFO.: US 1991-715948 19910614
WO 1992-US5118 19920612
US 1992-981149 19921124

OTHER SOURCE(S): MARPAT 119:73118
GI



I

AB Peptide derivs. R7ONHCOCHRCHR1CONHCR2R9-B-X-D [R and R1 = H, alkyl, aryl, aralkyl; R2 = (un)substituted aralkyl or heterocyclic alkyl; B = CONR6, R6NCO, CH2SO, CH2SO2, CH2NH, COCH2, CH:CH, C(OH)CH2NH2, CO-AA1 (AA1 =

amino acid residue), X = bond, alkylene, (CR5R10)mCONR8, (CR5R10)mCH2O, (CR5R10)mCO2; R9 and R10 = H, Me or Et; D, R5, R6, R7, and R8 = H or alkyl; m = 1, 2, 3] were prepared as collagenase inhibitors. Thus, Me2CHCH2CH(CO2H)CH2CO2CMe3 was coupled with H-L-Nal-L-Ala-NH2.HCl (Nal = naphthylalanine) by EtN:C:N(CH2)3NMe2 (EDC) in the presence of Et3N in DMF to give the corresponding condensed product, which was sequentially de-tert-butylated by HCl/dioxane, condensed with H2NOCH2Ph by EDC and debenzylated by hydrogenolysis to give peptide derivative I as a mixture of 2 diastereoisomers. The peptide derivs. were assayed for enzyme-inhibiting activity using pig synovial collagenase, pig synovial gelatinase, and recombinant human fibroblast collagenase.

IT **148745-35-1 148745-36-2 148745-37-3**
148745-38-4 148811-73-8 148811-74-9
148811-75-0 148811-76-1 148811-77-2
148811-78-3 148811-79-4 148811-80-7
148811-81-8 148811-82-9 148811-83-0
148811-84-1 148811-85-2 148811-86-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(collagenase-inhibiting activity of)

RN 148745-35-1 HCAPLUS
CN L-Alaninamide, 4-chloro-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, (R)- (9CI) (CA INDEX NAME)



RN 148745-36-2 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methoxy-O-methyl-L-tyrosyl-, (R)- (9CI) (CA INDEX NAME)



RN 148745-37-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-N-methyl-, (R)- (9CI) (CA INDEX NAME)



RN 148745-38-4 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxymethylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, (R)- (9CI) (CA INDEX NAME)



RN 148811-73-8 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148811-74-9 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, (S)- (9CI) (CA INDEX NAME)



RN 148811-75-0 HCAPLUS
CN L-Alaninamide, 4-chloro-N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, (S)- (9CI) (CA INDEX NAME)



RN 148811-76-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methoxy-O-methyl-L-tyrosyl-, (S)- (9CI) (CA INDEX NAME)



RN 148811-77-2 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-N-methyl-, (S)- (9CI) (CA INDEX NAME)



RN 148811-78-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 148811-79-4 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 148811-80-7 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 148811-81-8 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 148811-82-9 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 148811-83-0 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 148811-84-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 148811-85-2 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-L-tryptophyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 148811-86-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxymethylamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl-, (S)- (9CI) (CA INDEX NAME)



IT **148745-00-0P 148745-09-9P 148811-56-7P**
148811-66-9P 148811-67-0P 148811-68-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and collegenase-inhibiting activity of)
RN 148745-00-0 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, (R)- (9CI) (CA INDEX NAME)



RN 148745-09-9 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)



RN 148811-56-7 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, (S)- (9CI) (CA INDEX NAME)



RN 148811-66-9 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)



RN 148811-67-0 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Searched by P. Ruppel



RN 148811-68-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



IT **148745-39-5P 148745-40-8P 148745-43-1P**
148811-88-5P 148812-14-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 148745-39-5 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148745-40-8 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(3-pyridinyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148745-43-1 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148811-88-5 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methoxy-O-methyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148812-14-0 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(1-naphthalenyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 56 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:829 HCAPLUS
DOCUMENT NUMBER: 118:829
TITLE: Mammalian matrix metalloprotease inhibitors for treatment of tissue ulceration
INVENTOR(S): Galardy, Richard E.; Grobelny, Damian; Schultz, Gregory
PATENT ASSIGNEE(S): University of Florida, USA
SOURCE: U.S., 13 pp.
CODEN: USXXAM
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5114953	A	19920519	US 1990-616021	19901121
CA 2096223	AA	19920522	CA 1991-2096223	19911121
CA 2096223	C	20020924		
WO 9209282	A1	19920611	WO 1991-US8721	19911121
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9191351	A1	19920625	AU 1991-91351	19911121
AU 652016	B2	19940811		
EP 558681	A1	19930908	EP 1992-902666	19911121
EP 558681	B1	19980408		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508164	T2	19931118	JP 1992-502805	19911121
JP 06102626	B4	19941214	JP 1991-502805	19911121
AT 164767	E	19980415	AT 1992-902666	19911121
ES 2115668	T3	19980701	ES 1992-902666	19911121
US 5270326	A	19931214	US 1992-881630	19920512
NO 9301803	A	19930518	NO 1993-1803	19930518
US 5892112	A	19990406	US 1994-184727	19940121
US 5773438	A	19980630	US 1994-464927	19940605

PRIORITY APPLN. INFO.:

US 1990-477751	B2	19900209
US 1990-615798	A2	19901121
US 1990-616021	A	19901121
US 1991-747751	A1	19910820
US 1991-747752	A2	19910820

WO 1991-US8721	A	19911121
US 1992-817039	A2	19920107
US 1992-881630	A1	19920512
US 1993-44324	A2	19930407
US 1994-184727	A3	19940121

OTHER SOURCE(S): MARPAT 118:829

AB A method to treat or prevent ulceration of tissue comprises administering an effective amount of a mammalian matrix metalloprotease inhibitor HONHCOCR1HCR2HCON(R3)CR4HCOX or HONHCOC(R1)=C(R2)CON(R3)C(R4)HCOX [R1 = H; R2 = C3-8 alkyl; or R1 and R2 together = (CH2)n; n = 3-5; R3 = H C1-4 alkyl; R4 = fused or conjugated (un)substituted bicycloaryl methylene; X = OR5, NHR5, amino acid residue, amide of amino acid residue, cyclic amine residue, heterocyclic amine residue; R5 = H, (un)substituted C1-12 alkyl, C6-12 aryl, C6-16 arylalkyl]. NHOHCOCH2CH(iso-Bu)CO-L-TrpNHMe (I) inhibited human skin fibroblast collagenase with a Ki = 10 nM. I prevented corneal ulceration in alkali-burned rabbit cornea.

IT **142880-58-8P 142880-59-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in ulcer inhibitor preparation)

RN 142880-58-8 HCAPLUS

CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-59-9 HCAPLUS

CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, monopotassium salt (9CI) (CA INDEX NAME)



● K

IT **142880-36-2P 142880-37-3P 142880-38-4P**

142880-40-8P 142880-46-4P 142880-50-0P
142880-53-3P 142880-57-7P 142880-60-2P
142880-62-4P 142880-75-9P 142902-71-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as ulcer inhibitor)

RN 142880-36-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-38-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-40-8 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-46-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-50-0 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-53-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-57-7 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-60-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-75-9 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142902-71-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



L20 ANSWER 57 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:651774 HCAPLUS
DOCUMENT NUMBER: 117:251774
TITLE: Preparation of substituted amino acids as matrix metalloprotease inhibitors
INVENTOR(S): Galardy, Richard E.; Grobelny, Damian
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9209556	A1	19920611	WO 1991-US8723	19911121
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5183900	A	19930202	US 1990-615798	19901121
US 5189178	A	19930223	US 1991-747752	19910820
CA 2096221	AA	19920522	CA 1991-2096221	19911121
AU 9190958	A1	19920625	AU 1991-90958	19911121
AU 662504	B2	19950907		
EP 558648	A1	19930908	EP 1992-901322	19911121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508163	T2	19931118	JP 1992-501548	19911121
JP 2736285	B2	19980402	JP 1991-501548	19911121
NO 9301841	A	19930519	NO 1993-1841	19930519

PRIORITY APPLN. INFO.: US 1990-615798 A 19901121
US 1991-747752 A 19910820
WO 1991-US8723 A 19911121

OTHER SOURCE(S): MARPAT 117:251774

AB Title compds. R7ONR6CO(CHR1)nCHR2CONR3CHR4COX and R7ONR6CO(CHR1)mCR1:CR2CONR3CHR4COX [R1 = H, C1-8 alkyl; R2 = C1-8; or R1R2 = (CH2)p wherein p = 3-5; R3, R6 = H, C1-4 alkyl; R4 = fused or conjugated (substituted) bicycloarylmethylene; n = 0-2; m = 0, 1; X = R5O, R5NH wherein R5 = H, (substituted) C1-12 alkyl, C6-12 aryl, C6-16 alkylaryl, amino acid, amide, cyclic amine heterocyclic amine; R7 = H, C1-4 alkyl, acyl, and wherein CONR3 is optionally in modified isosteric form], are prepared To a mixture of MeO2CCH2CH(CH2CHMe2)CO2H (preparation given) and (COCl)2 in CH2Cl2 was added DMT at room temperature to give an intermediate to which was added L-tryptophan (S)-methylbenzylamide to give after workup

HONHCOCH2CH(Me2CHCH2)CO-L-Trp-NH-(S)-CHMePhe (I). I inhibited metalloprotease with Ki of 3 mM.

IT **143985-51-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and neutralization of)

RN 143985-51-7 HCAPLUS

CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, monopotassium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

IT **142880-36-2P 142880-37-3P 142880-38-4P**
142880-53-3P 142880-58-8P 142880-60-2P
142880-62-4P 142880-75-9P 143985-20-0P
143985-22-2P 143985-24-4P 143985-25-5P
144007-85-2P 144007-86-3P 144007-87-4P
144007-88-5P 144007-89-6P 144022-77-5P
144022-78-6P 144069-98-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as metalloprotease inhibitor)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-

2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-38-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-53-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-58-8 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-60-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-75-9 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-20-0 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-22-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-24-4 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-25-5 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144007-85-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N4-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-86-3 HCAPLUS
CN Butanediamide, N4-ethyl-N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-87-4 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-88-5 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N4-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144007-89-6 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N4-ethyl-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144022-77-5 HCAPLUS
CN Butanediamide, N1-[2-(ethylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-methoxy-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144022-78-6 HCAPLUS
CN Butanediamide, N4-ethoxy-N1-[2-(ethylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-methyl-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 144069-98-7 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)-, [2S-[N1[R*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 58 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:612958 HCAPLUS
DOCUMENT NUMBER: 117:212958
TITLE: Preparation of substituted amino acids as matrix metalloprotease inhibitors
INVENTOR(S): Galardy, Richard E.; Grobelny, Damian; Musser, John H.
PATENT ASSIGNEE(S): Glycomed, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9209563	A1	19920611	WO 1991-US8722	19911121
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5183900	A	19930202	US 1990-615798	19901121
US 5239078	A	19930824	US 1991-747751	19910820
AU 9190897	A1	19920625	AU 1991-90897	19911121
AU 661289	B2	19950720		
CA 2096225	AA	19930221	CA 1991-2096225	19911121
EP 558635	A1	19930908	EP 1992-901119	19911121
EP 558635	B1	19970910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 07080825	B4	19950830	JP 1991-501333	19911121
AT 157963	E	19970915	AT 1992-901119	19911121
ES 2109335	T3	19980116	ES 1992-901119	19911121
NO 9301844	A	19930709	NO 1993-1844	19930519

PRIORITY APPLN. INFO.: US 1990-615798 A 19901121
US 1991-747751 A 19910820
US 1991-615798 A 19911121
WO 1991-US8722 A 19911121

OTHER SOURCE(S): MARPAT 117:212958

AB Title compds. Y(CHR1)nCHR2CONR3CHR4COX and Y(CHR2)mCR1:CR2CONR3CHR4COX (R1 = H, C1-8 alkyl; R2 = C1-8 alkyl; or R1R2 = (CH2)p wherein p = 3-5; R3 = H, C1-4 alkyl; R4 = (substituted) fused or conjugated bicycloarylmethylene; n = 0-2; m = 0, 1; X = R5O, R5NH wherein R5 = H, (substituted) C1-12 alkyl, C6-12 aryl, C6-16 arylalkyl, amino or amide residue, cyclic amine or heterocyclyl; Y = R7ONR6CONR6, (R6)2NCONOR7, R6CONOR7 wherein R6 = H, C1-4 alkyl; R7 = C1-4 alkyl, acyl; CONR3 is optionally in modified

isosteric form], are prepared To a mixture of MeO2CCH2CH(CH2CHMe2)CO2H (preparation given) and (COCl)2 in CH2Cl2, anhydrous DMF was added, and to the residue obtained was added L-tryptophan (S)-methylbenzylamide to give NHOHCOCH2CH(CH2CHMe)2CO-L-Trp-NH-(S)-CHMePh (I). I inhibited metalloprotease with Ki of 3 μM.

IT **143985-51-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and neutralization of)

RN 143985-51-7 HCAPLUS

CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, monopotassium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

IT **142880-36-2P 142880-37-3P 142880-38-4P**
142880-53-3P 142880-58-8P 142880-62-4P
142880-75-9P 143985-20-0P 143985-22-2P
143985-24-4P 143985-25-5P 144069-98-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as metalloprotease inhibitor)

RN 142880-36-2 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-37-3 HCAPLUS

CN Butanediamide, N4-hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-

2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-38-4 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-53-3 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-(pentylamino)ethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-58-8 HCAPLUS
CN Butanediamide, N1-[2-(dodecylamino)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-62-4 HCAPLUS
CN Carbamic acid, [6-[[(2S)-2-[[(2S)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]-3-(1H-indol-3-yl)-1-oxopropyl]amino]hexyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142880-75-9 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1R)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-20-0 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-N1-methyl-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-22-2 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[2-[(2-hydroxyethyl)amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-24-4 HCAPLUS
CN Butanediamide, N4-(acetyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143985-25-5 HCAPLUS
CN Butanediamide, N4-(benzoyloxy)-N1-[1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 144069-98-7 HCAPLUS
CN Butanediamide, N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[(1-phenylethyl)amino]ethyl]-2-(2-methylpropyl)-, [2S-[N1[R*(R*)],2R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 59 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:559788 HCAPLUS
DOCUMENT NUMBER: 115:159788
TITLE: Preparation of (hydroxyamino) amino acids as collagenase inhibitors
INVENTOR(S): Campion, Colin; Davidson, Alan Hornsby; Dickens, Jonathan Philip; Crimmin, Michael John
PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9102716	A2	19910307	WO 1990-GB1117	19900720
WO 9102716	A3	19910627		
W: AU, CA, FI, JP, KR, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2064786	AA	19910225	CA 1990-2064786	19900720
AU 9060454	A1	19910403	AU 1990-60454	19900720
AU 639706	B2	19930805		

EP 489032	A1	19920610	EP 1990-911398	19900720
EP 489032	B1	19940914		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05501864	T2	19930408	JP 1990-510523	19900720
JP 2871849	B2	19990317		
ES 2063975	T3	19950116	ES 1990-911398	19900720
US 5453438	A	19950926	US 1992-820664	19920116
NO 9200702	A	19920423	NO 1992-702	19920221
US 5910609	A	19990608	US 1995-417095	19950405
PRIORITY APPLN. INFO.:			GB 1989-19251	19890824
			WO 1990-GB1117	19900720

OTHER SOURCE(S): MARPAT 115:159788
GI



II

AB Title compds. HONHCOCHR1CHR2CONHCHR3CONR4R5 [I; R1 = H, C1-6 alkyl, C1-6 alkenyl, phenyl-C1-6 alkylthiomethyl, (substituted) phenylthiomethyl, heterocyclthiomethyl, etc.; R2 = H, C1-6 alkyl, C1-6 alkenyl, cycloalkyl-C1-6-alkyl, etc.; R3 = amino acid side chain, C1-6 alkyl, PhCH2, PhCH2OPhCH2, etc.; R4 = H, Me; R5 = hydroxyalkyl, C1-6 alkoxyalkyl, phenylthioalkyl, C2-7 acylaminoalkyl, etc.; R4R5N = hydroxymethyl-, carboxyheterocyclyl], salt, N-oxide, sulfoxide, sulfone thereof, are prepared I are useful in promotion of wound healing (no data). [4-(4-Benzyloxyamino-2R-isobutylsuccinyl]-L-phenylalanine (preparation given) was coupled with EtSCH2CH2NH2.HCl, and the product hydrogenated to give the amide II. In test for collagenase inhibition activity II showed an IC50 of 20 μM. Pharmaceutical formulations comprising I are given.

IT **135775-00-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 135775-00-7 HCAPLUS

CN Butanediamide, N1-[2-[[2-(acetylamino)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-N4-hydroxy-2-(2-methylpropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 60 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:590468 HCAPLUS
DOCUMENT NUMBER: 113:190468
TITLE: Preparation and formulation of hydroxamic acid derivatives as collagenase inhibitors
INVENTOR(S): Davidson, Alan Hornsby; Dickens, Jonathan Philip; Crimmin, Michael John
PATENT ASSIGNEE(S): British Bio-Technology Ltd., UK
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9005716	A1	19900531	WO 1989-GB1398	19891123
W: AU, DK, FI, JP, NO, US				
RW: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE				
CA 2003719	AA	19900523	CA 1989-2003719	19891123
AU 9047468	A1	19900612	AU 1990-47468	19891123
AU 641629	B2	19930930		
EP 445206	A1	19910911	EP 1990-900268	19891123
EP 445206	B1	19940316		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04503057	T2	19920604	JP 1990-500815	19891123
AT 102919	E	19940415	AT 1990-900268	19891123
ES 2063334	T3	19950101	ES 1990-900268	19891123
JP 2846737	B2	19990113	JP 1989-500815	19891123
US 5304604	A	19940419	US 1991-674363	19910415
DK 9100967	A	19910522	DK 1991-967	19910522
NO 9101963	A	19910708	NO 1991-1963	19910522
NO 177700	B	19950731		
NO 177700	C	19951108		
US 5514677	A	19960507	US 1994-229154	19940418

PRIORITY APPLN. INFO.:
GB 1988-27308 19881123
EP 1990-900268 19891123
WO 1989-GB1398 19891123
US 1991-674363 19910415

OTHER SOURCE(S): CASREACT 113:190468; MARPAT 113:190468
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Hydroxamic acid derivs. [I; R1 = H, C1-6 alkyl, alkenyl, Ph, OS, etc.; R2 = H, C1-6 alkyl, alkenyl, phenylalkyl, etc.; R1 = amino acid residue, C2-6 alkyl, PhCH2, etc.; R4 = H, Me; n = 1-6; A = NH2, substituted acyclic amino, heterocycle residue, etc.], their N-oxides, sulfoxides, or sulfones, having collagenase inhibitory activity useful in treating arthropathy, inflammation, dematolog. diseases, bone resorption diseases, and tumor invasion (no data), are prepared and formulated. Saponification of Me ester (2R)-L-II (R = Me) with LiOH in MeOH gave 71% and (2R)-L-II (R = H), which was dissolved in THF and treated with pyrrolidine derivative III, Et3N,

and ClCO2Et to give 72% (2R,2'RS)-L-IV. Also prepared were 38 addnl. I which showed collagenase inhibitory activity with IC50 = 15-70 nM. Tablet, capsule, injection, suppository, and ointment formulations were given.

IT **130128-39-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 130128-39-1 HCAPLUS

CN Butanediamide, N1-[2-[[2-(diethylamino)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-N4-hydroxy-3-methyl-2-(2-methylpropyl)-, [2R-[1(S*),2R*,3S*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 61 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:412332 HCAPLUS
DOCUMENT NUMBER: 111:12332
TITLE: Hair tonics containing proteoglycanase inhibitors, glycosaminoglycanase inhibitors, and inhibitors of cellular uptake of glycosaminoglycans
PATENT ASSIGNEE(S): Unilever N. V., Neth.
SOURCE: Jpn. Kokai Tokkyo Koho, 38 pp.
CODEN: JKXXAF
DOCUMENT TYPE: **Patent**
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 63166823	A2	19880711	JP 1987-326597	19871223
JP 03029764	B4	19910425		
CA 1319889	A1	19930706	CA 1987-554275	19871214
US 5015470	A	19910514	US 1987-134422	19871217
AU 8782813	A1	19880623	AU 1987-82813	19871218
AU 615170	B2	19910926		
ZA 8709564	A	19890830	ZA 1987-9564	19871221
IN 166979	A	19900811	IN 1987-BO370	19871221
EP 277428	A2	19880810	EP 1987-311315	19871222
EP 277428	A3	19910313		
EP 277428	B1	19940323		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
AT 103165	E	19940415	AT 1987-311315	19871222
ES 2051758	T3	19940701	ES 1987-311315	19871222
BR 8707033	A	19880802	BR 1987-7033	19871223

PRIORITY APPLN. INFO.: GB 1986-30721 19861223
EP 1987-311315 19871222

AB Hair tonics are prepared which contain enzyme inhibitors, such as

proteoglycanase inhibitors, glycosaminoglycanase inhibitors, and inhibitors of cell uptake of glycosaminoglycans, and vehicles as carriers of these inhibitors. Thus, a hair lotion was prepared consisting of L-galactono-1,4-lactone 0.1, EtOH 99.995% by weight and a perfume q.s. Thirty other hair lotions and tonics were prepared

IT **106314-87-8**
RL: BIOL (Biological study)
(proteoglycanase inhibitor, hair tonic containing)

RN 106314-87-8 HCAPLUS

CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 62 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:167973 HCAPLUS

DOCUMENT NUMBER: 108:167973

TITLE: Preparation of (hydroxylamino)acylpeptides as inhibitors of synovial collagenase

INVENTOR(S): Handa, Balraj Krishnan; Johnson, William Henry; Machin, Peter James

PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.

SOURCE: Eur. Pat. Appl., 24 pp.
CODEN: EPXXDW

DOCUMENT TYPE: **Patent**

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 236872	A2	19870916	EP 1987-102771	19870226
EP 236872	A3	19890913		
EP 236872	B1	19921125		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
DK 8700774	A	19870912	DK 1987-774	19870216
AT 82753	E	19921215	AT 1987-102771	19870226
CA 1314655	A1	19930316	CA 1987-530988	19870303
ZA 8701563	A	19871028	ZA 1987-1563	19870304
IL 81790	A1	19910310	IL 1987-81790	19870305
AU 8769902	A1	19870917	AU 1987-69902	19870311
AU 588437	B2	19890914		
JP 62230757	A2	19871009	JP 1987-56412	19870311
JP 06029228	B4	19940420		
US 4996358	A	19910226	US 1989-336264	19890411

PRIORITY APPLN. INFO.:

GB 1986-5977	19860311
GB 1986-29712	19861212
US 1987-14957	19870217

EP 1987-102771 19870226

AB ACHR3CHR1CONHCHR2CONR6CHR4R5 [I; A = HN(OH)CO, HCON(OH); R1 = alkyl; R2 = side chain of naturally-occurring amino acid, not H, Me; R2R4 = (CH2)n; R3 = H, amino, OH, SH, alkyl, alkoxy, alkylthio, arylalkyl, etc.; R4, R6 = H, Me; R5 = H, R4R5 = (CH2)3; alkyl, alkoxyalkyl, dialkoxymethylene, carboxy, acyl, carbamoyl; n = 4-11] and pharm. acceptable salts were prepared for treatment of degenerative joint disease. [2(R)-Isobutylsuccinyl]-L-leucyl-L-alanine Et ester (preparation given) in THF at -15° was treated with iso-Bu chloroformate and N-ethylmorpholine followed by O-benzylhydroxylamine. The resulting benzyloxyamino derivative was hydrogenoylzed in EtOH over 5% Pd/C to give 4-N-hydroxylaminol-2(R)-isobutylsuccinyl]-L-leucyl-L-alanine Et ester. The latter inhibited human synovial collagenase with an IC50 of 8.5 + 10-9 M.

IT **112105-86-9P 112105-87-0P 112105-88-1P**
112105-89-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of, in preparation of collagenase inhibitor)

RN 112105-86-9 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-leucyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-87-0 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-valyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-88-1 HCAPLUS
CN Glycinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-leucyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-89-2 HCAPLUS
CN Glycinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-lysyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **112105-58-5P 112105-59-6P 112105-60-9P**
112105-61-0P 112105-63-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)
RN 112105-58-5 HCAPLUS
CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-59-6 HCAPLUS
CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-60-9 HCAPLUS
CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-61-0 HCAPLUS
CN Glycinamide, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-lysyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 112105-63-2 HCAPLUS
CN Glycinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-O-methyl-L-tyrosyl-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 63 OF 63 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1988:150980 HCAPLUS
DOCUMENT NUMBER: 108:150980
TITLE: Preparation of hydroxyamino peptides as metalloprotease inhibitors
INVENTOR(S): Shaw, Andrew; Wolanin, Donald John
PATENT ASSIGNEE(S): ICI Americas, Inc., USA
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: **Patent**
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 231081	A2	19870805	EP 1987-300366	19870116
EP 231081	A3	19891115		
EP 231081	B1	19930317		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4771038	A	19880913	US 1987-2814	19870113
AT 87005	E	19930415	AT 1987-300366	19870116
ES 2053525	T3	19940801	ES 1987-300366	19870116
JP 62228097	A2	19871006	JP 1987-9207	19870120
JP 2532859	B2	19960911		

PRIORITY APPLN. INFO.: GB 1986-1368 19860121
EP 1987-300366 19870116

AB HONHCO(CH2)n CHR1CONHCHR2CONHCHR3CONHA (I; R1 = alkyl; R2, R3, R4 = amino acid residue; A = H, CHR4CONH2; n = 1, 2) and pharmaceutically acceptable salts and maleate esters were prepared as metalloprotease inhibitors (no data). O-Benzylhydroxylamine was added to dihydro-3-pentyl-2,5-furandione in THF at -20° and the mixture was stirred 1 h at -20° to give 2-[2-oxo-2-(phenylmethoxyamino)ethyl]heptanoic acid. The latter in THF was treated with N-methylmorpholine and EtO2CCl at -15° for 1 h and coupled with H-Leu-Phe-NH2 in Me2SO at room temperature overnight. The product was debenzylated in MeOH over Pd/C to give I (R1 = pentyl, R2 = CH2CHMe2, R3 = CH2Ph, A = H, n = 1).

IT **113614-66-7P 113614-71-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)

RN 113614-66-7 HCAPLUS
CN L-Phenylalaninamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 113614-71-4 HCAPLUS
CN L-Leucinamide, N-[4-methyl-1-oxo-2-[2-oxo-2-[(phenylmethoxy)amino]ethyl]pentyl]-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **106314-87-8P 113614-62-3P 113614-70-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as metalloprotease inhibitor)
RN 106314-87-8 HCAPLUS
CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 113614-62-3 HCAPLUS
CN L-Alaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 113614-70-3 HCAPLUS
CN L-Leucinamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b home
FILE 'HOME' ENTERED AT 10:03:54 ON 04 MAY 2004